EP3906253A1 - Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions - Google Patents
Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditionsInfo
- Publication number
- EP3906253A1 EP3906253A1 EP19702500.0A EP19702500A EP3906253A1 EP 3906253 A1 EP3906253 A1 EP 3906253A1 EP 19702500 A EP19702500 A EP 19702500A EP 3906253 A1 EP3906253 A1 EP 3906253A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide analog
- conotoxin peptide
- pharmaceutically acceptable
- acceptable salt
- pegylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 1161
- 108050003126 conotoxin Proteins 0.000 title claims description 1096
- 208000002193 Pain Diseases 0.000 title claims description 81
- 230000036407 pain Effects 0.000 title claims description 75
- 230000004968 inflammatory condition Effects 0.000 title claims description 17
- 238000000034 method Methods 0.000 claims abstract description 187
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 166
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 164
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims abstract description 159
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims abstract description 159
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 52
- 230000005764 inhibitory process Effects 0.000 claims abstract description 51
- 230000002265 prevention Effects 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims description 271
- 229920000642 polymer Polymers 0.000 claims description 136
- JBZXBEBRZLKCGN-BYPYZUCNSA-N (2s)-2-(2-diazohydrazinyl)pentanoic acid Chemical compound CCC[C@@H](C(O)=O)NN=[N+]=[N-] JBZXBEBRZLKCGN-BYPYZUCNSA-N 0.000 claims description 77
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 70
- SCGJGNWMYSYORS-UHFFFAOYSA-N homoproparglyglycine Natural products OC(=O)C(N)CCC#C SCGJGNWMYSYORS-UHFFFAOYSA-N 0.000 claims description 58
- DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical compound OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 claims description 54
- NNWQLZWAZSJGLY-VKHMYHEASA-N (2s)-2-azaniumyl-4-azidobutanoate Chemical compound OC(=O)[C@@H](N)CCN=[N+]=[N-] NNWQLZWAZSJGLY-VKHMYHEASA-N 0.000 claims description 51
- 125000005647 linker group Chemical group 0.000 claims description 50
- 230000015572 biosynthetic process Effects 0.000 claims description 38
- 125000003368 amide group Chemical group 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 37
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 35
- 206010061218 Inflammation Diseases 0.000 claims description 34
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 34
- 230000004054 inflammatory process Effects 0.000 claims description 34
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 33
- 150000001413 amino acids Chemical group 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 30
- KRCVJTNGGWBYEW-REOHCLBHSA-N (2s)-2-(2-diazohydrazinyl)propanoic acid Chemical compound OC(=O)[C@H](C)NN=[N+]=[N-] KRCVJTNGGWBYEW-REOHCLBHSA-N 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 150000003852 triazoles Chemical class 0.000 claims description 24
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 23
- 239000004471 Glycine Substances 0.000 claims description 21
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 19
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 19
- 235000013477 citrulline Nutrition 0.000 claims description 19
- 229960002173 citrulline Drugs 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 16
- 208000004296 neuralgia Diseases 0.000 claims description 14
- 201000001119 neuropathy Diseases 0.000 claims description 14
- 230000007823 neuropathy Effects 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 13
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 11
- 229920001427 mPEG Polymers 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- 229940070710 valerate Drugs 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 208000000094 Chronic Pain Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 6
- 208000028389 Nerve injury Diseases 0.000 claims description 5
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000008764 nerve damage Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 210000000578 peripheral nerve Anatomy 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 201000010260 leiomyoma Diseases 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- 108091058551 α-conotoxin Proteins 0.000 abstract description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 293
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 66
- 241000700159 Rattus Species 0.000 description 53
- 150000001875 compounds Chemical class 0.000 description 49
- 238000004128 high performance liquid chromatography Methods 0.000 description 48
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 43
- 229940126214 compound 3 Drugs 0.000 description 38
- -1 hexafluorophosphate Chemical compound 0.000 description 36
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 33
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 30
- 230000014759 maintenance of location Effects 0.000 description 30
- 239000000203 mixture Substances 0.000 description 25
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 20
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- 230000036515 potency Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 159000000021 acetate salts Chemical class 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 238000010647 peptide synthesis reaction Methods 0.000 description 15
- 239000007790 solid phase Substances 0.000 description 15
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 14
- 208000004454 Hyperalgesia Diseases 0.000 description 14
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 13
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 13
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 13
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 12
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 12
- 229960004373 acetylcholine Drugs 0.000 description 12
- 230000006320 pegylation Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000000202 analgesic effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 238000006317 isomerization reaction Methods 0.000 description 10
- 229960004441 tyrosine Drugs 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000000105 evaporative light scattering detection Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 8
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 210000000287 oocyte Anatomy 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 101100330292 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-12 gene Proteins 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 6
- 229960001756 oxaliplatin Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- DVBUCBXGDWWXNY-GOSISDBHSA-N (2r)-5-(diaminomethylideneazaniumyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoate Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCCNC(=N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-GOSISDBHSA-N 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- ZHKQIADIIYMFOZ-UHFFFAOYSA-N 2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)C)C3=CC=CC=C3C2=C1 ZHKQIADIIYMFOZ-UHFFFAOYSA-N 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000013222 sprague-dawley male rat Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- IISRBJULQYVYGV-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hex-5-ynoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC#C)C(=O)O)C3=CC=CC=C3C2=C1 IISRBJULQYVYGV-IBGZPJMESA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 description 3
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 3
- 229930195709 D-tyrosine Natural products 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 238000010640 amide synthesis reaction Methods 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 150000003951 lactams Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- YWCKIQCRKHNUOY-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hept-6-ynoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC#C)C(=O)O)C3=CC=CC=C3C2=C1 YWCKIQCRKHNUOY-FQEVSTJZSA-N 0.000 description 2
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 2
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 2
- HWYLVHOPQMLNRJ-NAKBKFBQSA-N 76862-65-2 Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H](CC(N)=O)C(=O)N3CCC[C@H]3C(=O)N[C@H](C(N[C@@H](CSSC[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N2)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)C)C(N)=O)C1=CC=C(O)C=C1 HWYLVHOPQMLNRJ-NAKBKFBQSA-N 0.000 description 2
- 101710135856 Alpha-conotoxin GI Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000237970 Conus <genus> Species 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical group [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- DJGMNCKHNMRKFM-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pent-4-ynoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC#C)C(=O)O)C3=CC=CC=C3C2=C1 DJGMNCKHNMRKFM-SFHVURJKSA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- CIFCKCQAKQRJFC-REOHCLBHSA-N (2s)-2-amino-3-azidopropanoic acid Chemical compound OC(=O)[C@@H](N)CN=[N+]=[N-] CIFCKCQAKQRJFC-REOHCLBHSA-N 0.000 description 1
- TVPIDQLSARDIPX-SFHVURJKSA-N (2s)-5-azido-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=[N+]=[N-])C(=O)O)C3=CC=CC=C3C2=C1 TVPIDQLSARDIPX-SFHVURJKSA-N 0.000 description 1
- JYPHNHPXFNEZBR-MRVPVSSYSA-N (R)-3-Amino-3-(4-hydroxy-phenyl)-propionic acid Chemical compound OC(=O)C[C@@H](N)C1=CC=C(O)C=C1 JYPHNHPXFNEZBR-MRVPVSSYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101710133013 Alpha-conotoxin SI Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 101100348341 Caenorhabditis elegans gas-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical group [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical class [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100447658 Mus musculus Gas1 gene Proteins 0.000 description 1
- 101100447665 Mus musculus Gas2 gene Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- AUARUCAREKTRCL-BYPYZUCNSA-N [(4s)-4-amino-4-carboxybutyl]-diazonioazanide Chemical compound OC(=O)[C@@H](N)CCCN=[N+]=[N-] AUARUCAREKTRCL-BYPYZUCNSA-N 0.000 description 1
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
- PDKXJKWLFFZPPF-UHFFFAOYSA-N [dimethylamino-(3-oxidotriazolo[4,5-b]pyridin-3-ium-1-yl)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(C(N(C)C)=[N+](C)C)N=[N+]([O-])C2=N1 PDKXJKWLFFZPPF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003030 auditory receptor cell Anatomy 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- UMSRVAZBHUJACA-UOSOHNMVSA-N chembl405470 Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H](CC(N)=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N[C@H](C(NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N1)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(N)=O)C1=CC=C(O)C=C1 UMSRVAZBHUJACA-UOSOHNMVSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- KJQOYUHYAZGPIZ-PIJHVLQJSA-N conotoxin vc1.1 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H]2NC(=O)[C@@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC(O)=O)C(=O)N1)C(N)=O)=O)[C@@H](C)CC)C1=CN=CN1 KJQOYUHYAZGPIZ-PIJHVLQJSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical group CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical group [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- alpha-conotoxin peptide analogs including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs.
- PEG polyethylene glycol
- methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an a9- containing nicotinic acetylcholine receptor (nAChR) e.g., the a9a10 subtype of the nAChR
- neuropharmacologically active peptides conotoxin peptides or conotoxins
- conotoxin peptides or conotoxins neuropharmacologically active peptides
- Native alpha-conotoxin peptides are highly disulfide cross-linked peptides with a C1-C3 and C2-C4 disulfide bridge pattern (Azam and McIntosh, 2009, Acta Pharmacol. Sin. 30:771-783).
- Alpha-conotoxin peptides have generally been shown to be nicotinic acetylcholine receptor (nAChR) antagonists (Nicke et al., 2004, Eur. J. Biochem.271:2305-2319).
- nAChRs are pentameric ligand-gated ion channels assembled from one or more a subunits (a1- a10) either alone or together with one or more non-a subunits (b1-b4) (Sine and Engel, 2006, Nature 440:448-455).
- the a9a10 nAChR subunits are expressed in diverse tissues. In the inner ear, a9a10 nAChRs mediate synaptic transmission between efferent olivocochlear fibers and cochlear hair cells (Vetter et al., 1999, Neuron 23:93-103). The a9a10 subunits are also found in dorsal root ganglion neurons (Lips et al., 2002, Neuroscience 115:1-5), lymphocytes (Peng et al., 2004, Life. Sci.76:263-280), skin keratinocytes (Nguyen et al., 2000, Am. J.
- Pathol.157:1377-1391 the pars tuberalis of the pituitary (Elgoyhen et al., 1994, Cell 79:705-715; Zuo et al., 1999, Proc. Natl. Acad. Sci. USA 96:14100-14105).
- Compounds that have a pharmacological profile that includes a9a10 antagonist activity prevent or attenuate the expression of pain in several rodent models, including neuropathic pain induced by chemotherapy, traumatic nerve injury, and diabetes (see Hone and McIntosh, 2018, FEBS Lett.592:1045-1062).
- Native conotoxin peptide RgIA has the amino acid sequence Gly-Cys-Cys-Ser-Asp- Pro-Arg-Cys-Arg-Tyr-Arg-Cys-Arg (SEQ ID NO:1) (Ellison et al., 2008, J. Mol. Biol.
- Alpha-conotoxin peptide RgIA has been shown to block a9a10 nAChR activity (Romero et al., 2017, Proc. Natl. Acad. Sci. USA 14:E1825-E1832).
- RgIA belongs to the a-4/3 family of a-conotoxins.
- the native structure of RgIA is characterized by two compact intra-cysteine loops defined by two disulfide bonds formed between Cys2-Cys8 (sometimes referred CysI-CysIII) and Cys3-Cys12 (sometimes referred to CysII-CysIV) (Ellison et al, 2008, J. Mol. Biol.377:1216-1227; Armishaw, 2010, Toxins 2:1471-1499).
- the first and second cysteine residues are always adjacent, but the number of amino acid residues between the second and third cysteine, and between the third and fourth cysteine residues can vary. This gives rise to two loops of intervening amino acids denoted loop 1 or the m-loop and loop 2 or the n-loop. In RgIA, loop 1 contains 4 amino acids and loop 2 contains 3 amino acids. The disulfide bonds and therefore the secondary structure of a-conotoxins are unstable and subject to rearrangement (Armishaw, 2010, Toxins 2:1471-1499).
- the two disulfide bonds of the a-conopeptide are subject to rearrangement and can form alternative three-dimensional structures including a ribbon form (disulfide bonds Cys-2- Cys12 and Cys3-Cys8) and a bead form (disulfide bonds Cys2-Cys3 and Cys8-Cys12). While the native or globular form of the peptide is active on the a9a10-nAChr, neither the ribbon or bead form are thought to be active (Dekan et al., 2011, J. Am. Chem. Soc.133:15866-15869; Armishaw et al., 2006, J. Bio. Chem.281:14136-14143).
- Hargittai et al. evaluated four lactam-bridged derivatives of the alpha-conotoxin SI, and only one of the four lactam-bridged derivatives did not lose significant activity in binding to BC3H1 cells (Hargittai et al., 2000, J. Med. Chem.43:4787-4792).
- Bondebjerg et al. evaluated synthesized thioether mimetics of the alpha-conotoxin GI and found that the two isomers tested had significantly less pharmacologic activity than the native peptide (Bondebjerg et al., 2003, ChemBioChem 4:186-194).
- Non-reducible dicarba analogs of alpha-ImI were evaluated and in both instances found to have an approximately 10-fold reduction in pharmacological activity (MacRaild et al., 2009, J. Med. Chem.52:755-762). Certain specific selenocysteine and cystathionine derivatives of ImI retained activity in blocking the rat a7 nAChR (Dekan et al., 2011, J. Am. Chem. Soc.133:15866-15869; Armishaw et al., 2006, J. Bio. Chem.281:14136- 14143).
- van Lierop evaluated dicarba substitutions of the disulfide bonds of alpha-conotoxin Vc1.1 and found that the [2,8]-cis and [2,8]-trans dicarba analogs had no activity on the rat a9a10 nAChr, whereas the [3,16]-cis and [3,16]-trans isomers of Vc1.1 had greatly reduced (10- 100-fold) activity on rat a9a10 nAChR (van Lierop et al., 2013, ACS Chemical Biology 8:1815- 1821). Yu et al created N-terminal to C-terminal peptide-linked derivatives of Vc1.1 that had one or more cysteine residues replaced with His or Phe.
- Native RgIA has approximately 300-fold lower affinity for the human than the rat a9a10 nAChR, and this difference in affinity has been mapped to variation in the amino acid sequence of the alpha 9 subunit within the RgIA binding pocket (Azam et al., 2015, Mol.
- Conotoxin peptides and their analogs are competitive inhibitors of the a9a10 nAChR and they bind at the ACh binding site, i.e., at the interface between adjacent subunits.
- the subunit interfaces buries to a 1.4 ⁇ probe radius, a surface area of ⁇ 1300 ⁇ , where these conotoxins interact with residues between subunits encompassing distances less than 5 ⁇
- Non-covalent or covalent attachment to polyethylene glycol polymer(s) can change the physical and chemical properties of a biomolecule such as a peptide, such as its conformation, electrostatic binding, and hydrophobicity (Veronese and Mero, 2008, BioDrugs, 22:315-329; see also Harris et al., 2001, Clin. Pharmacokinet.40:539-551).
- PEGylation of a therapeutic protein often leads to a loss in its binding affinity due to the steric hindrance of the PEG polymer to the drug-target binding interaction (Fishburn, 2008, J. Pharm. Sci.97:4167-4183).
- PEGylated therapeutic proteins can lose biological activity or potency, either through steric effects or through hydrophobic-hydrophobic interactions between the PEG and hydrophobic domains within the protein (Parrott and DeSimone, 2011, Nat. Chem. 4:13-14).
- AA is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- a A is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group.
- the triazole bridge is
- the triazole bridge is
- x is 1, 2, or 3.
- x is 1.
- y is 2 or 3.
- y is 3.
- x is 1, 2, or 3, and y is 2 or 3.
- x is 1 and y is 3.
- x is 2, and y is 3.
- x is 2, and y is 2.
- x is 1, and y is 3.
- x is 2, and y is 2.
- the triazole bridge is , wherein the single wavy line ( indicates the point of attachment of the triazole bridge to the C 1 carbon of the
- X is X 1
- X is X 1
- a A is selected from the group consisting of Tyr, D-Tyr and Phe.
- X is Tyr
- the C-terminus of the conotoxin peptide analog is OH.
- the C-terminus of the conotoxin peptide analog is NH 2 .
- the conotoxin peptide analog is of Formula (Ia) (SEQ ID NO: 1
- R 1 is OH or NH2.
- R 1 is OH.
- R 1 is NH2.
- the conotoxin peptide analog is of Formula (Ig) (SEQ ID NO: 1
- the conotoxin peptide analog is of Formula (Ih) (SEQ ID NO:
- the conotoxin peptide analog is of Formula (Ii) (SEQ ID NO:36):
- the conotoxin peptide analog is of Formula (Ik) (SEQ ID N).
- the conotoxin peptide analog is of Formula (Il) (SEQ ID N).
- the conotoxin peptide analog is of Formula (Im) (SEQ ID NO:
- the conotoxin peptide analog is of Formula (In) (SEQ ID NO: 1]
- the conotoxin peptide analog is of Formula (Io) (SEQ ID NO:
- the conotoxin peptide analog is of Formula (Ip) (SEQ ID NO: 1]
- conotoxin peptide analogs or pharmaceutically acceptable salt thereof wherein the conotoxin peptide analog is of Formula (I) (SEQ ID NO:93):
- a A is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- a A is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group
- conotoxin peptide analog is covalently attached directly or via a linking group to one or more polyethylene glycol (PEG) polymers.
- PEG polyethylene glycol
- the triazole bridge is wherein the single wavy line ( ndicates the point of
- the triazole bridge is [0059] In a specific embodiment, wherein the triazole bridge is [0060] In a specific embodiment, the triazole bridge is
- x is 1, 2, or 3.
- x is 1.
- y is 2 or 3.
- y is 3.
- x is 1, 2, or 3
- y is 2 or 3.
- x is 1 and y is 3.
- x is 2 and y is 3.
- x is 2 and y is 2.
- x is 1 and y is 3.
- x is 2 and y is 2.
- the triazole bridge is wherein the single wavy line ( ndicates the point of attachment of the triazole bridge to the C 1 carbon of the
- X is X 1
- X is X 1
- AA is selected from the group consisting of Tyr, D-Tyr and Phe.
- X is Tyr
- the C-terminus of the conotoxin peptide analog is OH.
- the C-terminus of the conotoxin peptide analog is NH2.
- the conotoxin peptide analog is of Formula (Ia) (SEQ ID NO:94)
- R 1 is OH
- R 1 is NH2.
- the conotoxin peptide analog is of Formula (Ig) (SEQ ID NO: 1]
- the conotoxin peptide analog is of Formula (Ih) (SEQ ID NO:33):
- the conotoxin peptide analog is of Formula (Ii) (SEQ ID NO:
- the conotoxin peptide analog is of Formula (Ik) (SEQ ID N).
- the conotoxin peptide analog is of Formula (Il) (SEQ ID NO:
- the conotoxin peptide analog is of Formula (Im) (SEQ ID N
- the conotoxin peptide analog is of Formula (In) (SEQ ID N).
- the conotoxin peptide analog is of Formula (Io) (SEQ ID NO:54)
- the conotoxin peptide analog is of Formula (Ip) (SEQ ID NO: 1]
- the conotoxin peptide analog is covalently attached to one PEG polymer.
- the PEG polymer is covalently attached to the N-terminus of the conotoxin peptide analog.
- the PEG polymer is covalently attached to the C-terminus of the conotoxin peptide analog.
- the PEG polymer is covalently attached to an amino acid residue position that is not the N-terminus or the C-terminus of the conotoxin peptide analog.
- the PEG polymer is covalently attached to the conotoxin peptide analog via a linking group.
- the linking group is a valerate linker having a formula of .
- the linking group is a butylene.
- the linking group is a carbonyl
- the PEG polymer is a linear or branched PEG polymer.
- the PEG polymer is a linear PEG polymer.
- the PEG polymer has molecular weight in the range of 10 kDa and 40 kDa.
- the PEG polymer is a linear 30 kDa PEG polymer.
- the PEG polymer is a linear 30 kDa mPEG polymer.
- the PEGylated conotoxin peptide analog is of Formula (IIa) (
- the PEGylated conotoxin peptide analog is of Formula ( li
- the PEGylated conotoxin peptide analog is of Formula ( li
- the PEGylated conotoxin peptide analog is of Formula (IIi) (
- the PEGylated conotoxin peptide analog is of Formula (
- the PEGylated conotoxin peptide analog is of Formula (IIl) (SEQ ID NO:99):
- the PEGylated conotoxin peptide analog is of Formula (
- the PEGylated conotoxin peptide analog is of Formula (
- the PEGylated conotoxin peptide analog is of Formula (IIo) (SEQ ID NO:102):
- the PEGylated conotoxin peptide analog is of Formula (
- R 2 is OH or NH 2 .
- R 2 is OH.
- R 2 is NH2.
- conotoxin peptide analogs or a pharmaceutically acceptable salt thereof, wherein the conotoxin peptide analog is of Formula (Ib) (SEQ ID NO:104):
- R 2 is OH or NH2
- conotoxin peptide analog is covalently attached directly or via a linking group to one or more polyethylene glycol (PEG) polymers.
- PEG polyethylene glycol
- R 2 is OH
- R 2 is NH2.
- the conotoxin peptide analog is covalently attached to one PEG polymer.
- the PEG polymer is covalently attached to the N-terminus of the conotoxin peptide analog.
- the PEG polymer is covalently attached to the C-terminus of the conotoxin peptide analog.
- the PEG polymer is covalently attached to an amino acid residue position that is not the N-terminus or the C-terminus of the conotoxin peptide analog.
- the PEG polymer is covalently attached to the conotoxin peptide analog via a linking group.
- the linking group is a valerate linker having a formula of .
- the linking group is a butylene.
- the linking group is a carbonyl
- the PEG polymer is a linear or branched PEG polymer.
- the PEG polymer is a linear PEG polymer.
- the PEG polymer has molecular weight in the range of 10 kDa and 40 kDa.
- the PEG polymer is a linear 30 kDa PEG polymer.
- the PEG polymer is a linear 30 kDa mPEG polymer.
- the PEGylated conotoxin peptide analog is of Formula (IIb) (SEQ ID NO:105):
- conotoxin peptide analogs selected from the group consisting of conotoxin peptide analogs Ia, Ia’, Ib, Ib’, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, Im, In, Io, Ip, Iq, Ir, Is, It, Iu, and Iv, or a pharmaceutically acceptable salt thereof.
- the conotoxin peptide analog is selected from the group consisting of conotoxin peptide analogs Ia, Ia’, Ib, Ib’, Ig, Ih, Ii, Ik, Il, Im, In, Io, and Ip.
- the conotoxin peptide analog is selected from the group consisting of conotoxin peptide analogs Ia, Ia’, Ib, and Ib’.
- compositions comprising a conotoxin peptide analog or pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog or pharmaceutically acceptable salt thereof described herein, and optionally a
- Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR) in a subject comprising administering to the subject a therapeutically effective amount of a conotoxin peptide analog or pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog or pharmaceutically acceptable salt thereof, or pharmaceutical composition described herein.
- nAChR nicotinic acetylcholine receptor
- Also provided herein are methods of treating or preventing a condition associated with activation of an a9-containing nicotinic acetylcholine receptor (nAChR) in a subject comprising administering to the subject a therapeutically effective amount of a conotoxin peptide analog or pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog or pharmaceutically acceptable salt thereof, or pharmaceutical composition described herein.
- nAChR nicotinic acetylcholine receptor
- the condition conducive to treatment or prevention by inhibition of the a9-containing nAChR is pain or inflammation.
- the condition is pain.
- the pain is selected from the group consisting of general pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, visceral pain, somatic pain, pain induced by peripheral nerve damage, pain induced by an inflammatory disorder, pain induced by a metabolic disorder, pain induced by cancer, pain induced by chemotherapy, pain induced by a surgical procedure, and pain induced by a burn.
- the pain is cancer-related chronic pain.
- condition conducive to treatment or prevention by inhibition of the a9-containing nAChR is an inflammatory condition.
- the inflammatory condition is selected from the group consisting of inflammation, chronic inflammation, a rheumatic disease, sepsis, fibromyalgia, inflammatory bowel disease, sarcoidosis, endometriosis, uterine fibroids, an inflammatory skin disease, an inflammatory condition of the lungs, a disease associated with inflammation of the nervous system, periodontal disease, and cardiovascular disease.
- the inflammatory condition is mediated by immune cells.
- the inflammatory condition is long-term inflammation and/or peripheral neuropathy following injury.
- the condition conducive to treatment or prevention by inhibition of the a9-containing nAChR is pain and inflammation.
- the condition conducive to treatment or prevention by inhibition of the a9-containing nAChR is inflammation and neuropathy.
- the condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor is a condition conducive to treatment or prevention by inhibition of an a9a10 subtype of nAChR.
- the subject is a human.
- Also provided herein are methods of treating or preventing pain or inflammation in a subject comprising administering to the subject a therapeutically effective amount of a conotoxin peptide analog or pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog or pharmaceutically acceptable salt thereof, or pharmaceutical composition described herein.
- conotoxin peptide analogs or pharmaceutically acceptable salt thereof or PEGylated conotoxin peptide analogs or pharmaceutically acceptable salt thereof, or pharmaceutical compositions described herein, for use in treating or preventing a condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR) in a subject.
- nAChR nicotinic acetylcholine receptor
- compositions comprising a conotoxin peptide analog or pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog or pharmaceutically acceptable salt thereof, for use in treating or preventing a condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR) in a subject.
- nAChR nicotinic acetylcholine receptor
- conotoxin peptide analog or pharmaceutically acceptable salt thereof or a PEGylated conotoxin peptide analog or pharmaceutically acceptable salt thereof, or pharmaceutical composition described herein, in the preparation of a medicament for treating or preventing a condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR) in a subject.
- conotoxin peptide analogs or a salt thereof wherein the amino acid sequence of the conotoxin peptide analog is
- AA is selected from the group consisting of (S)-propargyl glycine, (S)-azidoalanine, (S)- homopropargyl glycine, (S)-azidohomoalanine, (S)-azidonorvaline and (S)-bishomopropargyl glycine;
- AA Citrulline
- a A is selected from the group consisting of (S)-azidohomoalanine, (S)-homopropargyl glycine, (S)-azidonorvaline, and (S)-bishomopropargyl glycine;
- AA is selected from the group consisting of (S)-propargyl glycine, (S)- homopropargyl glycine, and (S)-bishomopropargyl glycine, X 12
- a A is (S)-azidohomoalanine or (S)-azidonorvaline; and when X 3
- a A is selected from the group consisting of (S)-azidoalanine, (S)-azidohomoalanine, and (S)-azidonorvaline, X 12
- AA is (S)-homopropargyl glycine or (S)- bishomopropargyl glycine;
- a A is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group.
- a A is (S)-propargyl glycine or (S)-azidoalanine.
- AA is (S)-azidonorvaline or (S)-bishomopropargyl glycine.
- a A is (S)-propargyl glycine and X AA is (S)- azidonorvaline.
- AA is (S)-homopropargyl glycine and X 12
- AA is (S)- azidonorvaline.
- a A is (S)-homopropargyl glycine and X 12
- a A is (S)- azidohomoalanine.
- AA is (S)-azidohomoalanine and X 12
- AA is (S)- homopropargyl glycine. [00162] In a specific embodiment, X 3
- AA is (S)-azidoalanine and X 12
- AA is (S)- bishomopropargyl glycine.
- X is X 1
- X is X 1
- AA is selected from the group consisting of Tyr, D-Tyr and Phe.
- X is Tyr
- the C-terminus of the conotoxin peptide analog is OH.
- the C-terminus of the conotoxin peptide analog is NH 2 .
- a A is (S)-propargyl glycine, X 12
- a A is (S)-azidonorvaline, X is Tyr.
- the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- the C-terminus of the conotoxin peptide analog is an amide group.
- a A is (S)-homopropargyl glycine, X 12
- a A is (S)- azidonorvaline, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-homopropargyl glycine, X 12
- a A is (S)- azidohomoalanine, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-azidohomoalanine, X 12
- a A is (S)-homopropargyl glycine, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-azidoalanine, X 12
- a A is (S)-bishomopropargyl glycine, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- AA is (S)-propargyl glycine
- AA is (S)-azidonorvaline
- X is Phe
- the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- AA is (S)-propargyl glycine
- AA is (S)-azidonorvaline, X is D-Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- AA is (S)-propargyl glycine
- AA is (S)-azidonorvaline
- X is Tyr-N-Me-Gly
- C-terminus of the conotoxin peptide analog is a carboxylic acid group
- AA is (S)-propargyl glycine
- AA is (S)-azidonorvaline
- X is Tyr-D-Tyr
- C-terminus of the conotoxin peptide analog is a carboxylic acid group
- a A is (S)-propargyl glycine, X 12
- a A is (S)-azidonorvaline, X is Tyr-N-Me-Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- conotoxin peptide analogs or a salt thereof wherein the amino acid sequence of the conotoxin peptide analog is
- AA is (S)-propargyl glycine
- AA Citrulline
- a A is 3-iodo-Tyr
- AA is (S)-azidonorvaline
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group.
- the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- the C-terminus of the conotoxin peptide analog is an amide group.
- a A is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- a A is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog of Formula (I) is a carboxylic acid or an amide group
- AA is selected from the group consisting of (S)-propargyl glycine, (S)-azidoalanine, (S)- homopropargyl glycine, (S)-azidohomoalanine, (S)-azidonorvaline and (S)-bishomopropargyl glycine;
- a A is Citrulline
- AA is selected from the group consisting of (S)-azidohomoalanine, (S)-homopropargyl glycine, (S)-azidonorvaline, and (S)-bishomopropargyl glycine;
- a A is selected from the group consisting of (S)-propargyl glycine, (S)- homopropargyl glycine, and (S)-bishomopropargyl glycine, X 12
- AA is (S)-azidohomoalanine or (S)-azidonorvaline; when X 3
- AA is selected from the group consisting of (S)-azidoalanine, (S)- azidohomoalanine, and (S)-azidonorvaline, X 12
- a A is (S)-homopropargyl glycine or (S)- bishomopropargyl glycine;
- X is as defined above for the conotoxin peptide analog of Formula (I).
- AA is (S)-propargyl glycine
- AA Citrulline
- a A is 3-iodo-Tyr
- AA is (S)-azidonorvaline
- amino acid sequence of the conotoxin peptide analog is Gly-Cys-X 3
- a A is selected from the group consisting of (S)-propargyl glycine, (S)-azidoalanine, (S)- homopropargyl glycine, (S)-azidohomoalanine, (S)-azidonorvaline and (S)-bishomopropargyl glycine;
- a A is Citrulline
- AA is selected from the group consisting of (S)-azidohomoalanine, (S)-homopropargyl glycine, (S)-azidonorvaline, and (S)-bishomopropargyl glycine;
- a A is selected from the group consisting of (S)-propargyl glycine, (S)- homopropargyl glycine, and (S)-bishomopropargyl glycine, X 12
- AA is (S)-azidohomoalanine or (S)-azidonorvaline; when X 3
- AA is selected from the group consisting of (S)-azidoalanine, (S)- azidohomoalanine, and (S)-azidonorvaline, X 12
- a A is (S)-homopropargyl glycine or (S)- bishomopropargyl glycine;
- AA is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- a A is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group.
- amino acid sequence of the conotoxin peptide analog is Gly-Cys-X 3
- a A is (S)-propargyl glycine
- AA Citrulline
- AA is 3-iodo-Tyr
- a A is (S)-azidonorvaline
- FIG.1A-FIG.1D Disulfide shuffling of CSP-4-NH2 in human serum.
- FIG.1A CSP-4-NH2 was spiked into human serum and incubated at 37 °C for the specified period, after which samples were frozen, purified by precipitation and filtration and analyzed by RP-HPLC. A time-dependent conversion of main peak to secondary peak with faster retention time was observed.
- FIG.1B Individual injections of synthetically constructed CSP-4-NH2 ribbon, bead and native isomers together with a sample of CSP-4-NH2 isolated from human serum were analyzed. Comigration of serum-derived peaks indicated conversion of the native form to the ribbon isomer .
- FIG.1C Isolation of serum-derived compound CSP-4-NH2 followed by lyophilization and mass spectrometry analysis indicated that both the native and ribbon isomer have the same mass-to-charge ratio.
- FIG.1D Conversion of the globular to ribbon form by glutathione reduction of CSP-4-NH2 indicated that disulfide shuffling underlies isomerization.
- FIG.2A-FIG.2B Reverse phase HPLC analyses of conotoxin peptide analog Ia and conotoxin peptide analog CSP-4-NH2 in rat plasma.
- FIG.2A reverse phase HPLC analyses of conotoxin peptide analog Ia at 0 h, 8 h and 24 h (black line: 0 h; dark grey line: 8 h; light grey line: 24 h)..
- FIG.2B reverse phase HPLC analyses of conotoxin peptide analog CSP-4-NH 2 (“native” form, consisting of two disulfide bonds, one between Cys2 and Cys8, and a second between Cys3 and Cys12) in rat plasma at 0 h, 8 h and 24 h (black line: 0 h; dark grey line: 8 h; light grey line: 24 h).
- FIG.3A-FIG.3B Concentration-response curves of conotoxin peptide analogs for inhibition of ACh-gated currents in the human a9a10 nAChR.
- FIG.3A Concentration-response curves of conotoxin peptide analogs Ia, Ia’ and Ib’ for inhibition of ACh-gated currents in the human a9a10 nAChR ( ⁇ : Ia; ⁇ : Ia’; ⁇ : Ib’).
- FIG.3B Concentration-response curves of conotoxin peptide analogs CSP-4-NH2 and CSP-4-OH for inhibition of ACh-gated currents in the human a9a10 nAChR ( ⁇ : CSP-4-NH2; ⁇ : CSP-4-OH).
- FIG.4 Comparison of the amino acid sequences of RgIA (SEQ ID NO:1), ImI (SEQ ID NO:2) and Vc1.1 (SEQ ID NO:3).
- FIG.5A-FIG.5B Concentration-response curves of conotoxin peptide analogs for inhibition of ACh-gated currents in the human a9a10 nAChR.
- FIG.5A Concentration-response curves of conotoxin peptide analogs CSP-4-OH and CSP-4-desTyr-OH for inhibition of ACh- gated currents in the human a9a10 nAChR ( ⁇ : CSP-4-OH; ⁇ : CSP-4-desTyr-OH).
- FIG. 5B Concentration-response curves of conotoxin peptide analogs 1a and 1q for inhibition of ACh-gated currents in the human a9a10 nAChR ( ⁇ : 1a; ⁇ : 1q).
- FIG.6A-FIG.6B Representative traces from an oocyte injected with either the human (left) or rat (right) a9a10 nAChR. ACh-gated currents before and after exposure to compound PEGyated conotoxin peptide analog IIa.
- FIG.6A Response to ACh of the human a9a10 nAChR.
- FIG.6B Response to ACh of the rat a9a10 nAChR.
- FIG.7A Pharmacokinetic profile of PEGylated conotoxin peptide analog IIa ( : 1 mg/kg IV administration; : 1 mg/kg SC administration).
- FIG.7B Pharmacokinetic profile of conotoxin peptide analog Ia ( : 1 mg/kg IV administration; 1 mg/kg SC administration).
- FIG.9 Analgesic efficacy and duration of effect of conotoxin peptide analog Ib’ in a rat chronic constriction injury (CCI) model ( ⁇ : 0.1 mg/kg/day of conotoxin peptide analog Ib’; ⁇ : vehicle).
- FIG.10A-FIG.10C Analgesic efficacy and duration of effect of conotoxin peptide analog CSP-4-NH2 and PEGylated derivatives of CSP-4-NH2 in rat CIPN model.
- FIG.10A Mechanical hyperalgesia was measured by Randall-Selitto testing, demonstrating analgesic efficacy (normalized response) of CSP-4-NH2 and PEGylated conotoxin peptides VIII and X in the rat CIPN model over 96 h post dose.
- FIG.10B Mechanical hyperalgesia was measured by Randall-Selitto testing, demonstrating analgesic efficacy (normalized response) of CSP-4-NH2 and PEGylated conotoxin peptides VII, IX, XI and XII in the rat CIPN model over 96 h post dose.
- FIG.10C Summary plot of duration of efficacy of CSP-4-NH2 and PEGylated derivatives of CSP-4-NH2 showed that duration of efficacy correlates with both PEGylation conjugation chemistry (branch vs. linear) and conjugated PEG polymer size.
- FIG.11A-FIG.11C Analgesic efficacy and duration of effect of conotoxin peptide analogs Ia’, Ia, and PEGylated conotoxin peptide analog IIa in a rat chemotherapy induced peripheral neuropathy (CIPN) model.
- FIG.11A Administration of a single 0.5 mg/kg dose of conotoxin peptide analog Ia’ to rats having oxaliplatin-induced peripheral neuropathy, 14 days following induction of neuropathy, resulted in a statistically significant reduction in mechanical hyperalgesia compared to vehicle treated control animals for up to 24 h. ( ⁇ : 0.5 mg/kg of conotoxin peptide analog Ia’; ⁇ : vehicle).
- FIG.11B Administration of a single 0.5 mg/kg dose of Ia’ to rats with spared nerve injury on day 14 following surgical induction of the model resulted in a statistically significant reduction in mechanical hyperalgesia compared to vehicle treated control animals for up to 24 h ( ⁇ : 0.5 mg/kg of conotoxin peptide analog Ia’; ⁇ :
- FIG.11C Administration of a single 0.5 mg/kg dose of conotoxin peptide analog Ia or PEGylated conotoxin peptide analog IIa to rats with oxaliplatin-induced peripheral neuropathy, 14 days following induction of neuropathy, resulted in a significant reduction in mechanical hyperalgesia compared to vehicle treated control animals for up to 4 h (conotoxin peptide analog Ia) or 72 h conotoxin peptide analog Ia) post dose ( vehicle; : conotoxin peptide analog Ia; PEGylated conotoxin peptide analog IIa).
- Mechanical hyperalgesia was measured by Randall Selitto paw withdrawal threshold in grams. The endpoint for all studies was the Randall Siletto paw withdrawal threshold in grams. Two-way ANOVA, *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001. 5.
- alpha-conotoxin peptide analogs including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs.
- PEG polyethylene glycol
- nAChR nicotinic acetylcholine receptor
- amino acids According to the single letter or three letter codes.
- the amino acids forming all or a part of a peptide may be from among the known 21 naturally occurring amino acids, which are referred to by both their single letter abbreviations and their common three-letter abbreviation.
- conventional amino acid residues have their conventional meaning.
- “Leu” is leucine
- “Ile” is isoleucine
- “Nle” is norleucine
- AA is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group.
- the triazole bridge is
- the single wavy line ( ) indicates the point of attachment of the triazole bridge to the C 1 carbon of the conotoxin peptide analog
- the double wavy lines ( indicate the point of attachment of the triazole bridge to the C 2 carbon of the conotoxin peptide analog
- x is 1, 2, 3, or 4
- y is 2, 3 or 4.
- the triazole bridge is
- the triazole bridge is
- x is 1, 2, 3, or 4. In one preferred embodiment, x is 1, 2, or 3. In a specific embodiment, x is 1 or 2. In one embodiment, x is 1. In another embodiment, x is 2.
- y is 2, 3, or 4. In a specific embodiment, y is 2 or 3. In one embodiment, y is 3. In another embodiment, y is 2.
- x is 1, 2 or 3, and y is 2 or 3. In a specific embodiment, x is 1, 2, or 3, and y is 2. In a specific embodiment, x is 1, 2, or 3, and y is 3. In a specific embodiment, x is 1 or 2, and y is 2 or 3. In a specific embodiment, x is 1 or 3, and y is 2 or 3. In a specific embodiment, x is 2 or 3, and y is 2 or 3. In a specific embodiment, x is 1, and y is 2 or 3. In a specific embodiment, x is 2, and y is 2 or 3. In a specific embodiment, x is 3, and y is 2 or 3. In one preferred embodiment, x is 1 and y is 3. In one preferred embodiment, x is 2 and y is 3. In one preferred embodiment, x is 2 and y is 2.
- the triazole bridge is , wherein the single wavy line ( ) indicates the point of attachment of the triazole bridge to the C 1 carbon of the conotoxin peptide analog, and the double wavy lines ( ) indicate the point of attachment of the triazole bridge to the C 2 carbon of the conotoxin peptide analog.
- the triazole bridge is , wherein the single wavy line ( ) indicates the point of attachment of the triazole bridge to the C 1 carbon of the conotoxin peptide analog, and the double wavy lines ( ) indicate the point of attachment of the triazole bridge to the C 2 carbon of the conotoxin peptide analog.
- X is X 1 2
- X is X 1
- a A is Tyr, Phe, Trp, or a D- isomer of Tyr, Phe, or Trp.
- AA is Tyr, Phe, or Trp.
- X 1 is Trp.
- AA is Tyr, D- Tyr, or Phe.
- X 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-N- Tyr, or Phe.
- AA is Tyr or D-Tyr.
- X 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-N-Tyr.
- AA is Tyr or Phe.
- X 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethy
- a A is D-Tyr or Phe.
- a A is Phe.
- AA is D-Phe.
- X 1 is N-Phe.
- AA is Trp.
- X 1 is Trp.
- AA is D-Trp.
- X 1 is D-Trp.
- AA is D-Tyr.
- X 1 is D-Tyr.
- a A is Tyr. [00213] In a specific embodiment, X 2
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr.
- X 2 is N-Me-Gly, D-Tyr, or N-Me-Tyr.
- a A is N-Me-Gly or D-Tyr.
- X 2 is N-Me-Gly or D-Tyr.
- a A is D-Tyr or N-Me- Tyr.
- X 2 is N-Me- Tyr.
- a A is N-Me-Gly or N-Me-Tyr.
- X 2 is N-Me-Gly or N-Me-Tyr.
- AA is N-Me-Gly.
- X 2 is N-Me-Gly.
- AA is N-Me-Tyr.
- X 2 is N-Me-Tyr.
- AA is D-Tyr.
- AA is optionally present.
- X 2 is optionally present.
- a A is present.
- a A is absent.
- X is selected from the group consisting of Tyr, Phe, D-Tyr, (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), (Tyr)-(N-Me-Tyr), N-Me-Tyr, D-Arg, N-Me-D-Tyr, beta-Tyr, and N-Me-Arg.
- X is selected from the group consisting of Tyr, Phe, D-Tyr, (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), and (Tyr)-(N-Me-Tyr).
- X is selected from the group consisting of Tyr, Phe, and D-Tyr. In a specific embodiment, X is selected from the group consisting of (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), and (Tyr)-(N-Me-Tyr). In a specific embodiment, X is selected from the group consisting of N-Me-Tyr, D-Arg, N-Me- D-Tyr, beta-Tyr, and N-Me-Arg. In a specific embodiment, X is Tyr. In a specific embodiment, X is Phe. In a specific embodiment, X is D-Tyr.
- X is (Tyr)-(D-Tyr). In a specific embodiment, X is (Tyr)-(N-Me-Gly). In a specific embodiment, X is (Tyr)-(N-Me- Tyr). In a specific embodiment, X is N-Me-Tyr. In a specific embodiment, X is D-Arg. In a specific embodiment, X is N-Me-D-Tyr. In a specific embodiment, X is beta-Tyr. In a specific embodiment, X is N-Me-Arg.
- the C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group. In one preferred embodiment, the C-terminus of the conotoxin peptide analog is OH. In a specific embodiment, the C-terminus of the conotoxin peptide analog is NH 2 .
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ia) (SEQ ID NO:94):
- R 1 is OH or NH 2 .
- R 1 is OH.
- R 1 is NH2.
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ig) (SEQ ID NO:30):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ih) (SEQ ID NO:33):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ii) (SEQ ID NO:36):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ik) (SEQ ID NO:42):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Il) (SEQ ID NO:45):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Im) (SEQ ID NO:48):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (In) (SEQ ID NO:51):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Io) (SEQ ID NO:54):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ip) (SEQ ID NO:57):
- conotoxin peptide analogs of Formula (Ib) (SEQ ID NO:104):
- R 2 is OH or NH2.
- R 2 is OH. In a specific embodiment, R 2 is NH2.
- conotoxin peptide analogs selected from the group consisting of conotoxin peptide analogs Ia, Ia’, Ib, Ib’, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Il, Im, In, Io, Ip, Iq, Ir, Is, It, Iu, and Iv, or a pharmaceutically acceptable salt thereof.
- the conotoxin peptide analog is selected from the group consisting of conotoxin peptide analogs Ia, Ia’, Ib, Ib’, Ig, Ih, Ii, Ik, Il, Im, In, Io, and Ip.
- the conotoxin peptide analog is selected from the group consisting of conotoxin peptide analogs Ia, Ia’, Ib, and Ib’. In one preferred embodiment, the conotoxin peptide analog is conotoxin peptide analog Ia or Ia’. In one preferred embodiment, the conotoxin peptide analog is conotoxin peptide analog Ia. 5.3. PEGylated Conotoxin Peptide RgIA Analogs
- the conotoxin peptide analogs of the invention are PEGylated, in particular, covalently attached to one or more PEG polymers.
- a conotoxin peptide analog is covalently attached to one PEG polymer. In a specific embodiment, a conotoxin peptide analog is covalently attached to more than one PEG polymers. In a specific embodiment, a conotoxin peptide analog is covalently attached to two PEG polymers. In a specific embodiment, a conotoxin peptide analog is covalently attached to three PEG polymers. [00233] In a preferred embodiment, a PEG polymer is covalently attached to the N-terminus of a conotoxin peptide analog, most preferably one PEG polymer is attached only to the N- terminus.
- a PEG polymer is covalently attached to the C-terminus of a conotoxin peptide analog. In a specific embodiment, a PEG polymer is covalently attached to an amino acid residue position that is not the N-terminus or the C-terminus of the conotoxin peptide analog.
- a PEG polymer is covalently attached to the conotoxin peptide analog via a linking group. In a specific embodiment, a PEG polymer is covalently attached to the conotoxin peptide analog directly.
- the linking group is a valerate linker having a formula
- the linking group is a butylene.
- the linking group is a butylene.
- the linking group is a carbonyl.
- the PEG polymer is a linear or branched PEG polymer. In a specific embodiment, the PEG polymer is a branched PEG polymer. In one preferred embodiment, the PEG polymer is a linear PEG polymer.
- the PEG polymer has a molecular weight in the range of 10 kDa and 40 kDa. In one preferred embodiment, the PEG polymer is a 30 kDa PEG polymer. In specific embodiments, the PEG polymer is a linear 30 kDa PEG polymer. In specific
- the PEG polymer is a linear 30 kDa mPEG polymer.
- one PEG polymer is attached at the amino terminus of a conotoxin peptide analog, and the PEG polymer is attached via a linking group to the conotoxin peptide analog, and the linking group is a valerate linker having a formula o
- the PEG polymer is a linear 30 kDa mPEG polymer.
- a PEGylated conotoxin peptide analog or pharmaceutically acceptable salt thereof wherein the conotoxin peptide analog is of Formula (I) (SEQ ID NO:93):
- AA is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group
- conotoxin peptide analog is covalently attached directly or via a linking group to one or more polyethylene glycol (PEG) polymers.
- PEG polyethylene glycol
- the triazole bridge is
- the single wavy line ( ) indicates the point of attachment of the triazole bridge to the C 1 carbon of the conotoxin peptide analog
- the double wavy lines ( ) indicate the point of attachment of the triazole bridge to the C 2 carbon of the conotoxin peptide analog
- x is 1, 2, 3, or 4
- y is 2, 3 or 4.
- the triazole bridge is
- the triazole bridge is
- x is 1, 2, 3, or 4. In one preferred embodiment, x is 1, 2, or 3. In a specific embodiment, x is 1 or 2. In one embodiment, x is 1. In another embodiment, x is 2.
- y is 2, 3, or 4. In a specific embodiment, y is 2 or 3. In one embodiment, y is 3. In another embodiment, y is 2. [00243] In a specific embodiment, x is 1, 2 or 3, and y is 2 or 3. In a specific embodiment, x is 1, 2, or 3, and y is 2. In a specific embodiment, x is 1, 2, or 3, and y is 3. In a specific embodiment, x is 1 or 2, and y is 2 or 3. In a specific embodiment, x is 1 or 3, and y is 2 or 3. In a specific embodiment, x is 2 or 3, and y is 2 or 3. In a specific embodiment, x is 1, and y is 2 or 3. In a specific embodiment, x is 1, and y is 2 or 3.
- x is 2, and y is 2 or 3. In a specific embodiment, x is 3, and y is 2 or 3. In one preferred embodiment, x is 1 and y is 3. In one preferred embodiment, x is 2 and y is 3. In one preferred embodiment, x is 2 and y is 2.
- the triazole bridge is , wherein the single wavy line ( indicates the point of attachment of the triazole bridge to the C 1 carbon of the
- the triazole bridge is , wherein the single wavy line ( indicates the point of attachment of the triazole bridge to the C 1 carbon of the
- X is X 1
- X is X 1 2
- a A is Tyr, Phe, Trp, or a D- isomer of Tyr, Phe, or Trp.
- AA is Tyr, Phe, or Trp.
- X 1 is Trp.
- AA is Tyr, D- Tyr, or Phe.
- X 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-N- Tyr, or Phe.
- a A is Tyr or D-Tyr.
- a A is Tyr or Phe.
- a A is D-Tyr or Phe.
- a A is Phe.
- AA is D-Phe.
- X 1 is N-Phe.
- AA is Trp.
- X 1 is Trp.
- AA is D-Trp.
- X 1 is D-Trp.
- AA is D-Tyr.
- X 1 is D-Tyr.
- a A is Tyr.
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr.
- X 2 is N-Me-Gly, D-Tyr, or N-Me-Tyr.
- AA is N-Me-Gly or D-Tyr.
- X 2 is N-Me-Gly or D-Tyr.
- AA is D-Tyr or N-Me- Tyr.
- X 2 is N-Me- Tyr.
- a A is N-Me-Gly or N-Me-Tyr.
- X 2 is N-Me-Gly or N-Me-Tyr.
- AA is N-Me-Gly.
- X 2 is N-Me-Gly.
- AA is N-Me-Tyr.
- X 2 is N-Me-Tyr.
- a A is D-Tyr.
- a A is optionally present.
- X 2 is optionally present.
- a A is present.
- a A is absent.
- X is selected from the group consisting of Tyr, Phe, D-Tyr, (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), (Tyr)-(N-Me-Tyr), N-Me-Tyr, D-Arg, N-Me-D-Tyr, beta-Tyr, and N-Me-Arg.
- X is selected from the group consisting of Tyr, Phe, D-Tyr, (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), and (Tyr)-(N-Me-Tyr).
- X is selected from the group consisting of Tyr, Phe, and D-Tyr. In a specific embodiment, X is selected from the group consisting of (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), and (Tyr)-(N-Me-Tyr). In a specific embodiment, X is selected from the group consisting of N-Me-Tyr, D-Arg, N-Me- D-Tyr, beta-Tyr, and N-Me-Arg. In a specific embodiment, X is Tyr. In a specific embodiment, X is Phe. In a specific embodiment, X is D-Tyr.
- X is (Tyr)-(D-Tyr). In a specific embodiment, X is (Tyr)-(N-Me-Gly). In a specific embodiment, X is (Tyr)-(N-Me- Tyr). In a specific embodiment, X is N-Me-Tyr. In a specific embodiment, X is D-Arg. In a specific embodiment, X is N-Me-D-Tyr. In a specific embodiment, X is beta-Tyr. In a specific embodiment, X is N-Me-Arg.
- the C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group. In one preferred embodiment, the C-terminus of the conotoxin peptide analog is OH. In a specific embodiment, the C-terminus of the conotoxin peptide analog is NH2.
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ia) (SEQ ID NO:94):
- R 1 is OH or NH2. In a specific embodiment, R 1 is OH. In a specific embodiment, R 1 is NH 2 .
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ig) (SEQ ID NO:30):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ih) (SEQ ID NO:33):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ii) (SEQ ID NO:36):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ik) (SEQ ID NO:42):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Il) (SEQ ID NO:45):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Im) (SEQ ID NO:48):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (In) (SEQ ID NO:51):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Io) (SEQ ID NO:54):
- the conotoxin peptide analog or pharmaceutically acceptable salt of Formula (I) is of Formula (Ip) (SEQ ID NO:57):
- the PEGylated conotoxin peptide analog is of Formula (IIa) (
- the PEGylated conotoxin peptide analog is of Formula (IIg) (
- the PEGylated conotoxin peptide analog is of Formula (IIh) (SEQ ID NO:96):
- the PEGylated conotoxin peptide analog is of Formula (IIi) (
- the PEGylated conotoxin peptide analog is of Formula (IIk) (
- the PEGylated conotoxin peptide analog is of Formula (IIl) (SEQ ID NO:99):
- the PEGylated conotoxin peptide analog is of Formula (IIm) (
- the PEGylated conotoxin peptide analog is of Formula (IIn) (
- the PEGylated conotoxin peptide analog is of Formula (IIo) (SEQ ID NO:102):
- the PEGylated conotoxin peptide analog is of Formula (IIp) (
- PEGylated conotoxin peptide analogs or a pharmaceutically acceptable salt thereof wherein the conotoxin peptide analog is of Formula (Ib) (SEQ ID NO:104):
- conotoxin peptide analog is covalently attached directly or via a linking group to one or more polyethylene glycol (PEG) polymers.
- PEG polyethylene glycol
- R 2 is OH. In a specific embodiment of Formula (Ib), R 2 is NH 2 .
- the PEGylated conotoxin peptide analog is of Formula (IIb) (SEQ ID NO:105):
- compositions which comprise a conotoxin peptide analog provided herein or a PEGylated conotoxin peptide analog provided herein, and one or more pharmaceutically acceptable carriers.
- a conotoxin peptide analog is present in a therapeutically effective amount.
- a conotoxin peptide analog is present in a prophylactically effective amount.
- the pharmaceutical compositions can be used in accordance with the methods and uses provided herein. Thus, for example, the pharmaceutical compositions can be administered to a subject in order to practice the treatment or prevention methods and uses provided herein.
- Pharmaceutical compositions provided herein can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein.
- compositions typically comprise a therapeutically effective amount of at least one of the conotoxin peptide analogs or PEGylated conotoxin peptide analogs provided herein, and a pharmaceutically acceptable carrier.
- suitable pharmaceutically acceptable carriers include, but are not limited to, antioxidants (e.g., ascorbic acid), preservatives (e.g., benzyl alcohol, methyl parabens, p-hydroxybenzoate), emulsifying agents, suspending agents, dispersing agents, solvents, buffers, lubricants, fillers, and/or diluents.
- a suitable vehicle may be physiological saline solution.
- Typical buffers that can be used include, but are not limited to pharmaceutically acceptable weak acids, weak bases, or mixtures thereof.
- Buffer components can also include water soluble reagents such as phosphoric acid, tartaric acids, succinic acid, citric acid, acetic acid, and salts thereof.
- a vehicle may contain other pharmaceutically acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, or stability of the pharmaceutical composition.
- the vehicle is an aqueous buffer.
- a vehicle comprises, for example, sodium chloride.
- compositions provided herein may contain still other
- formulation agents for modifying or maintaining the rate of release of a conotoxin peptide analog described herein.
- formulation agents include, for example, those substances known to those skilled in the art in preparing sustained-release or controlled release formulations.
- pharmaceutically acceptable formulation agents see, for example, Remington’s Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa.18042) pages 1435-1712, and The Merck Index, 12th Ed. (1996, Merck Publishing Group, Whitehouse, NJ).
- a pharmaceutical composition is provided in a sterile vial as a solution, suspension, gel, emulsion, or dehydrated or lyophilized powder.
- compositions may, for example, be stored either in a ready to use form, a lyophilized form requiring reconstitution prior to use, or a liquid form requiring dilution prior to use.
- a pharmaceutical composition is provided in a single-use container (e.g., a single- use vial, ampoule, syringe, or autoinjector).
- a pharmaceutical composition is provided in a multi-use container (e.g., a multi-use vial or cartridge). Any drug delivery apparatus may be used to deliver a conotoxin peptide analog or a PEGylated conotoxin peptide analog or pharmaceutical composition described herein, including implants (e.g., implantable pumps) and catheters.
- depot injections can be utilized to release a conotoxin peptide analog or a PEGylated conotoxin peptide analog or pharmaceutical composition described herein over a defined period of time. Depot injections are generally administered subcutaneously or intramuscularly.
- a pharmaceutical composition can be formulated to be compatible with its intended route of administration as described herein.
- compositions may be in the form of a sterile injectable aqueous suspension.
- This suspension may be formulated using suitable dispersing or wetting agents and suspending agents known to those skilled in the art.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent.
- the sterile injectable solution can, for example, be a solution in 1,3- butane diol.
- Acceptable diluents, solvents or dispersion media include water, Ringer’s solution, saline, Cremophor ELTM, phosphate buffered saline (PBS), ethanol, polyol (e.g., glycerol or liquid polyethylene glycol), and mixtures thereof.
- Prolonged absorption of particular injectable formulations can be achieved by including an agent that delays absorption (e.g., aluminum monostearate or gelatin).
- compositions can also include carriers to protect the composition against degradation or elimination from the body.
- Various antibacterial and antifungal agents for example, parabens, chlorobutanol, ascorbic acid, thimerosal, can be included in the
- nAChR nicotinic acetylcholine receptor
- the condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor is a condition conducive to treatment or prevention by inhibition of the a9a10 subtype of nAChR.
- the condition conducive to treatment or prevention by inhibition of an a9-containing nAChR is pain or inflammation.
- an a9-containing nAChR e. g., the a9a10 subtype of nAChR
- the method provided herein is a method of treating a condition conducive to treatment by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR) comprising administering to a subject a therapeutically effective amount of a conotoxin peptide analog as described herein or a pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog as described herein or pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein.
- nAChR nicotinic acetylcholine receptor
- the condition conducive to treatment by inhibition of an a9-containing nicotinic acetylcholine receptor is a condition conducive to treatment by inhibition of the a9a10 subtype of nAChR.
- the condition conducive to treatment by inhibition of an a9-containing nAChR is pain or inflammation.
- the method provided herein is a method of preventing a condition conducive to prevention by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR) comprising administering to a subject a therapeutically effective amount of a conotoxin peptide analog as described herein or a pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog as described herein or pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein.
- nAChR nicotinic acetylcholine receptor
- the condition conducive to prevention by inhibition of an a9-containing nicotinic acetylcholine receptor is a condition conducive to treatment by inhibition of the a9a10 subtype of nAChR.
- the condition conducive to prevention by inhibition of an a9-containing nAChR is pain or inflammation.
- the condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor is pain.
- the pain is selected from the group consisting of general pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, pain induced by peripheral nerve damage, pain induced by an inflammatory disorder, pain induced by a metabolic disorder, pain induced by cancer, pain induced by chemotherapy, pain induced by a surgical procedure, and pain induced by a burn.
- the pain is cancer- related chronic pain.
- the pain is pain associated with neuropathy, which, by way of example, can be drug (e.g., cancer chemotherapeutic)-induced neuropathy or infection-induced neuropathy.
- the pain is neuralgia, including but not limited to postherpetic neuralgia, for example, postherpetic neuralgia due to shingles.
- the condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor is an inflammatory condition.
- the inflammatory condition is selected from the group consisting of is inflammation, chronic inflammation, a rheumatic disease, sepsis, fibromyalgia, inflammatory bowel disease, sarcoidosis, endometriosis, uterine fibroids, an inflammatory skin disease, an inflammatory condition of the lungs, a disease associated with inflammation of the nervous system, periodontal disease, and cardiovascular disease.
- the inflammatory condition is mediated by immune cells.
- the inflammatory condition is long-term inflammation and/or peripheral neuropathy following injury.
- the condition associated with the a9-containing nicotinic acetylcholine receptor e. g., the a9a10 subtype of nAChR
- the condition associated with the a9a10 subtype of nAChR condition is inflammation and neuropathy.
- a method of treating or preventing a condition associated with activation of an a9-containing nAChR, e. g., the a9a10 subtype of nAChR, in a subject comprising administering to the subject a therapeutically effective amount of a conotoxin peptide analog as described herein or pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog as described herein or pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein.
- a method of treating or preventing pain or inflammation in a subject comprising administering to the subject a therapeutically effective amount of a conotoxin peptide analog as described herein or pharmaceutically acceptable salt thereof, or a PEGylated conotoxin peptide analog as described herein or pharmaceutically acceptable salt thereof, or pharmaceutical composition as described herein.
- the pain is pain associated with neuropathy, which, by way of example, can be drug (e.g., cancer chemotherapeutic)-induced neuropathy or infection-induced neuropathy.
- the pain is neuralgia, including but not limited to postherpetic neuralgia, for example, postherpetic neuralgia due to shingles.
- the method provided herein is a method of treating pain or inflammation. In a specific embodiment, the method provided herein is a method of treating pain. In a specific embodiment, the method provided herein is a method of treating
- the method provided herein is a method of preventing pain or inflammation. In a specific embodiment, the method provided herein is a method of preventing pain. In a specific embodiment, the method provided herein is a method of preventing inflammation.
- the method of preventing pain is to prevent pain associated with neuropathy.
- the pain associated with neuropathy is neuralgia.
- the neuralgia is postherpetic neuralgia.
- the method of preventing pain is to prevent pain induced by cancer chemotherapy (and thus a conotoxin peptide analog or pharmaceutically acceptable salt thereof is administered to the patient prior to the patient being administered cancer chemotherapy).
- the method of preventing pain is to prevent pain induced by a surgical procedure; in a specific embodiment of such method, a conotoxin peptide analog or pharmaceutically acceptable salt thereof is administered prior to and/or concurrently with the surgical procedure, in particular, where the surgical procedure is reasonably expected to result in pain and/or inflammation.
- nAChR nicotinic acetylcholine receptor
- a method of inhibiting an a9-containing nicotinic acetylcholine receptor (nAChR), e.g., the a9a10 subtype of nAChR comprising administering to the subject a therapeutically effective amount of a conotoxin peptide analog as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein.
- nAChR nicotinic acetylcholine receptor
- “treat”,“treating”, treatment” and the like refer to an action (such as administering a conotoxin peptide analog or pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a conotoxin peptide analog or pharmaceutically acceptable salt thereof) initiated after a disease, disorder or condition, or a symptom thereof, has been diagnosed, observed, and the like so as to eliminate, reduce, suppress, mitigate, or ameliorate, either temporarily or permanently, at least one of the underlying causes of a disease, disorder, or condition afflicting a subject, or at least one of the symptoms associated with a disease, disorder, condition afflicting a subject.
- treatment can include inhibiting (i.e., arresting the development or further development of the disease, disorder or condition or clinical symptoms associated therewith) an active disease.
- the prevention need not be complete; in a specific embodiment, the prevention is partial inhibition or partial prevention or a reduction in the disease, condition or disorder relative to that which would otherwise be expected to occur absent the administration of the conotoxin peptide analog or pharmaceutically acceptable salt thereof.
- the administering can be by injecting or otherwise physically delivering a conotoxin peptide analog into a patient, such as by mucosal, intradermal, intravenous, intramuscular delivery and/or any other method of physical delivery described herein or known in the art.
- a disease, disorder or condition, or a symptom thereof is being treated, administration of the conotoxin peptide analog or pharmaceutically acceptable salt thereof typically occurs after the onset of disease, disorder or condition or symptom thereof.
- administration of the conotoxin peptide analog or pharmaceutically acceptable salt thereof typically occurs before the onset of the disease, disorder or condition or symptom thereof.
- a conotoxin peptide analog or pharmaceutically acceptable salt thereof is administered prior to and after the onset of pain and/or inflammation to both prevent and treat the pain and/or inflammation.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, as described herein, is used in any of the methods provided herein.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, provided herein can be used in a method for treatment or prevention of a disease or disorder or condition described herein.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, provided herein can be for use as a medicament.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, provided herein can be for use in a method for the treatment or prevention of a condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR), e.g. the a9a10 subtype of nAChR.
- nAChR nicotinic acetylcholine receptor
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, provided herein can be for use in a method for the treatment or prevention of a condition conducive to treatment or prevention by inhibition of an a9-containing nicotinic acetylcholine receptor (nAChR), e.g. the a9a10 subtype of nAChR.
- nAChR nicotinic acetylcholine receptor
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, provided herein can be for use in a method for the treatment or prevention of pain or inflammation.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, described herein may be administered to a patient by any of a variety of routes. These include, but are not limited to, parenteral, intra-articular, intranasal, intratracheal, oral, intradermal, topical, intramuscular, intraperitoneal, transdermal, intravenous, intratumoral, conjunctival, subcutaneous, and pulmonary routes.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, described herein is administered via subcutaneous administration.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, described herein is administered via intravenous administration.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, described herein is administered via intra-articular administration.
- a conotoxin peptide analog including but not limited to a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, to be administered to the patient will depend on the nature of the disease and the condition of the patient, and can be determined by standard clinical techniques and the knowledge of the physician.
- the precise dose and regime to be employed in a composition will also depend on the route of administration, and the seriousness of the disease, and should be decided according to the judgment of the physician and each patient's circumstance. Determination of the proper dosage can be determined by one skilled in the medical arts.
- the total daily dosage may be divided and administered in portions throughout the day or by means providing continuous delivery.
- a conotoxin peptide analog or pharmaceutically acceptable salt thereof is administered to a human subject at a dosage of between 0.01 to about 50 mg/kg of body weight.
- a conotoxin peptide analog e.g., a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, is administered to a human subject at a dosage of about 0.5 mg/kg of body weight.
- the human dose is from 1 to 1000 mg/day.
- the human daily dose is from 1 to 750 mg/day; or from 10 to 500 mg/day.
- a conotoxin peptide analog e.g., a PEGylated conotoxin peptide analog, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, disclosed herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens may be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. 5.7. Patients
- the patient referred to in this disclosure can be, but is not limited to, a human or non- human vertebrate such as a wild, domestic or farm animal.
- the patient is a mammal, e.g., a human, a cow, a dog, a cat, a goat, a horse, a sheep, a pig, a rabbit, a rat, or a mouse.
- the patient is a human patient.
- the human patient is an adult (at least age 16). In another specific embodiment, the human patient is an adolescent (age 12-15). In another specific embodiment, the patient is a child (under age 12). 5.8. Methods of Making Conotoxin Peptide Analogs [00311] This disclosure provides methods of making conotoxin peptide analogs, in which intermediate conotoxin peptide analogs (prior to triazole bridge formation) are subjected to triazole formation conditions to form the conotoxin peptide analogs of the invention. 5.8.1. Intermediate Conotoxin Peptide Analogs
- This disclosure provides syntheses of intermediate conotoxin peptide analogs for synthesizing conotoxin peptide analogs with a triazole bridge.
- An intermediate conotoxin peptide analog can, for example, be synthesized using solid phase peptide synthesis.
- necessary amino acids with appropriate reaction groups for example, an azide group or an acetylene group
- necessary amino acids can be introduced into the peptide (e.g., a conotoxin peptide of RgIA).
- the necessary amino acids can be introduced into the 3- and 12- position of the conotoxin peptide analog of RgIA.
- an amino acid residue bearing an acetylene group e.g., (S)-propargyl glycine, (S)-homopropargyl glycine, or (S)- bishomopropargyl glycine
- an amino acid bearing an azide group e.g., (S)-azidoalanine, (S)-azidohomoalanine, (S)-azidonorvaline
- the acetylene group and the azide group within the same intermediate conotoxin peptide can form a triazole ring when the intermediate conotoxin peptide is subjected to triazole formation conditions, thereby forming a triazole bridge in the resulting conotoxin peptide analog.
- the necessary amino acids for forming the triazole bridge are, for example, selected from the group of (S)-propargyl glycine, (S)-azidoalanine, (S)- homopropargyl glycine, (S)-azidohomoalanine, (S)-azidonorvaline, and (S)-bishomopropargyl glycine.
- AA is selected from the group consisting of (S)-propargyl glycine, (S)-azidoalanine, (S)- homopropargyl glycine, (S)-azidohomoalanine, (S)-azidonorvaline and (S)-bishomopropargyl glycine;
- AA Citrulline
- a A is selected from the group consisting of (S)-azidohomoalanine, (S)-homopropargyl glycine, (S)-azidonorvaline, and (S)-bishomopropargyl glycine;
- AA is selected from the group consisting of (S)-propargyl glycine, (S)- homopropargyl glycine, and (S)-bishomopropargyl glycine, X 12
- a A is (S)-azidohomoalanine or (S)-azidonorvaline; and when X 3
- a A is selected from the group consisting of (S)-azidoalanine, (S)-azidohomoalanine, and (S)-azidonorvaline, X 12
- AA is (S)-homopropargyl glycine or (S)- bishomopropargyl glycine;
- a A is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr
- AA is (S)-propargyl glycine or (S)-azidoalanine.
- a A is (S)-azidonorvaline or (S)-bishomopropargyl glycine.
- X 3 is (S)-azidonorvaline or (S)-bishomopropargyl glycine.
- a A is (S)-propargyl glycine and X 12
- a A is (S)-azidonorvaline.
- AA is (S)-homopropargyl glycine and X 12
- AA is (S)-azidonorvaline.
- X 3 is (S)-azidonorvaline.
- AA is (S)-homopropargyl glycine and X 12
- AA is (S)-azidohomoalanine.
- X 3 is (S)-azidohomoalanine.
- a A is (S)-azidohomoalanine and X 12
- a A is (S)-homopropargyl glycine.
- X 3 is (S)-homopropargyl glycine.
- AA is (S)-azidohomoalanine and X 12
- AA is (S)-homopropargyl glycine.
- X is X 1
- X is X 1 2
- a A is Tyr, Phe, Trp, or a D- isomer of Tyr, Phe, or Trp.
- AA is Tyr, Phe, or Trp.
- X 1 is Trp.
- AA is Tyr, D- Tyr, or Phe.
- X 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-N- Tyr, or Phe.
- a A is Tyr or D-Tyr.
- a A is Tyr or Phe.
- a A is D-Tyr or Phe.
- a A is Phe.
- AA is D-Phe.
- X 1 is N-Phe.
- AA is Trp.
- X 1 is Trp.
- AA is D-Trp.
- X 1 is D-Trp.
- AA is D-Tyr.
- X 1 is D-Tyr.
- a A is Tyr.
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr.
- X 2 is N-Me-Gly, D-Tyr, or N-Me-Tyr.
- AA is N-Me-Gly or D-Tyr.
- X 2 is N-Me-Gly or D-Tyr.
- AA is D-Tyr or N-Me- Tyr.
- X 2 is N-Me- Tyr.
- a A is N-Me-Gly or N-Me-Tyr.
- X 2 2 is N-Me-Gly or N-Me-Tyr.
- AA is N-Me-Gly. In a specific embodiment, XAA is N-Me-Tyr. In a specific embodiment, X 2
- AA is D-Tyr.
- AA is optionally present.
- X 2 is optionally present.
- a A is present.
- a A is absent.
- X is selected from the group consisting of Tyr, Phe, D-Tyr, (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), (Tyr)-(N-Me-Tyr), N-Me-Tyr, D-Arg, N-Me-D-Tyr, beta-Tyr, and N-Me-Arg.
- X is selected from the group consisting of Tyr, Phe, D-Tyr, (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), and (Tyr)-(N-Me-Tyr).
- X is selected from the group consisting of Tyr, Phe, and D-Tyr. In a specific embodiment, X is selected from the group consisting of (Tyr)-(D-Tyr), (Tyr)-(N-Me-Gly), and (Tyr)-(N-Me-Tyr). In a specific embodiment, X is selected from the group consisting of N-Me-Tyr, D-Arg, N-Me- D-Tyr, beta-Tyr, and N-Me-Arg. In a specific embodiment, X is Tyr. In a specific embodiment, X is Phe. In a specific embodiment, X is D-Tyr.
- X is (Tyr)-(D-Tyr). In a specific embodiment, X is (Tyr)-(N-Me-Gly). In a specific embodiment, X is (Tyr)-(N-Me- Tyr). In a specific embodiment, X is N-Me-Tyr. In a specific embodiment, X is D-Arg. In a specific embodiment, X is N-Me-D-Tyr. In a specific embodiment, X is beta-Tyr. In a specific embodiment, X is N-Me-Arg.
- the C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group. In one preferred embodiment, the C-terminus of the conotoxin peptide analog is OH. In a specific embodiment, the C-terminus of the conotoxin peptide analog is NH 2 .
- AA is (S)-propargyl glycine
- AA is (S)-azidonorvaline
- X is Tyr.
- the C-terminus of the conotoxin peptide analog is a carboxylic acid group. In another embodiment, the C-terminus of the conotoxin peptide analog is an amide group.
- AA is (S)-homopropargyl glycine, X 12
- AA is (S)- azidonorvaline, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- AA is (S)-homopropargyl glycine, X 12
- AA is (S)- azidohomoalanine, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- AA is (S)-azidohomoalanine, X 12
- AA is (S)-homopropargyl glycine, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- AA is (S)-azidoalanine, X 12
- AA is (S)-bishomopropargyl glycine, X is Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- AA is (S)-propargyl glycine
- AA is (S)-azidonorvaline, X is Phe; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-propargyl glycine, X 12
- a A is (S)-azidonorvaline, X is D-Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-propargyl glycine, X 12
- a A is (S)-azidonorvaline, X is Tyr-N-Me-Gly; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-propargyl glycine, X 12
- a A is (S)-azidonorvaline, X is Tyr-D-Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-propargyl glycine, X 12
- a A is (S)-azidonorvaline, X is Tyr-N-Me-Tyr; and wherein the C-terminus of the conotoxin peptide analog is a carboxylic acid group.
- a A is (S)-propargyl glycine
- AA Citrulline
- AA is 3-iodo-Tyr
- a A is (S)-azidonorvaline
- C-terminus of the intermediate conotoxin peptide analog is a carboxylic acid or an amide group.
- the C-terminus of the intermediate conotoxin peptide analog is a carboxylic acid group.
- the C-terminus of the intermediate conotoxin peptide analog is an amide group. 5.8.2. Triazole Bridge Formation
- a A is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- a A is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog of Formula (I) is a carboxylic acid or an amide group
- AA is selected from the group consisting of (S)-propargyl glycine, (S)-azidoalanine, (S)- homopropargyl glycine, (S)-azidohomoalanine, (S)-azidonorvaline and (S)-bishomopropargyl glycine;
- a A is Citrulline
- AA is selected from the group consisting of (S)-azidohomoalanine, (S)-homopropargyl glycine, (S)-azidonorvaline, and (S)-bishomopropargyl glycine;
- a A is selected from the group consisting of (S)-propargyl glycine, (S)- homopropargyl glycine, and (S)-bishomopropargyl glycine, X 12
- AA is (S)-azidohomoalanine or (S)-azidonorvaline; when X 3
- AA is selected from the group consisting of (S)-azidoalanine, (S)- azidohomoalanine, and (S)-azidonorvaline, X 12
- a A is (S)-homopropargyl glycine or (S)- bishomopropargyl glycine;
- X is as defined above for the conotoxin peptide analog of Formula (I).
- a A is (S)-propargyl glycine
- a A is Citrulline
- AA is 3-iodo-Tyr
- AA is (S)-azidonorvaline; and wherein the C-terminus of the intermediate conotoxin peptide analog is as defined above for the conotoxin peptide analog of Formula (Ib); and
- a A reacts with X AA to form a triazole bridge as depicted in the conotoxin peptide analog of Formula (Ib).
- the triazole formation conditions are conditions for“Click Chemistry” (i.e., 1,3-dipolar cycloaddition of azides and terminal alkynes) described in Hein et al. Pharm. Res.2008, 25(10): 2216-2230.
- the triazole formation conditions include presence of a copper catalyst.
- the triazole formation conditions include presence of a copper catalyst and a reducing reagent.
- the copper catalyst is a Cu(II) salt.
- the copper catalyst is CuSO4.
- the reducing reagent is L-ascorbic acid.
- the reducing reagent is sodium ascorbate.
- the triazole formation conditions include presence of a ruthenium catalyst. In one embodiment, the ruthenium catalyst is
- the triazole formation conditions are catalyst-free conditions.
- a salt of the conotoxin peptide analog of Formula (I) or (Ib) can be subjected to salt exchange steps to afford a pharmaceutically acceptable salt.
- a TFA salt of a conotoxin peptide analog of Formula (I) reacts with a base in an aqueous solution (pH 7.0-8.0) and then reacts with an appropriate acid to afford a pharmaceutically acceptable salt of the conotoxin peptide analog of Formula (I).
- the base is NH4HCO3 (aq.).
- the conotoxin peptide analog reacts with acetic acid to afford an acetate salt of the conotoxin peptide analog. 5.8.3.
- the synthesized conotoxin peptide analogs can further be covalently conjugated to one or more polyethylene glycol (PEG) polymers.
- PEG polyethylene glycol
- the conotoxin peptide analogs can, for example, be attached directly or via a linking group to one or more PEG polymers .
- a method of making a PEGylated conotoxin peptide analog or a pharmaceutically acceptable salt thereof comprising contacting under reaction conditions a conotoxin peptide analog or a salt thereof, with one or more reactive polyethylene glycol (PEG) polymers to form a PEGylated conotoxin peptide analog, wherein the reactive PEG polymers each comprise a reactive group covalently linked, optionally via a linking group, to a PEG polymer, and wherein each reactive group reacts under the reaction conditions to form a covalent bond with the conotoxin peptide analog whereby the conotoxin peptide analog is directly or via a linking group to the one or more PEG polymers.
- the conotoxin peptide analog is the conotoxin peptide analog is of Formula (I) (SEQ ID NO:93):
- a A is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- a A is N-Me-Gly, D-Tyr, or N-Me-Tyr;
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group
- conotoxin peptide analog is covalently attached directly or via a linking group to one or more polyethylene glycol (PEG) polymers.
- PEG polyethylene glycol
- a method of making a PEGylated conotoxin peptide analog or a pharmaceutically acceptable salt thereof comprising contacting under reaction conditions a conotoxin peptide analog or a salt thereof, with one or more reactive polyethylene glycol (PEG) polymers to form a PEGylated conotoxin peptide analog, wherein the reactive PEG polymers each comprise a reactive group covalently linked, optionally via a linking group, to a PEG polymer, and wherein each reactive group reacts under the reaction conditions to form a covalent bond with the conotoxin peptide analog whereby the conotoxin peptide analog is covalently attached directly or via a linking group to the one or more PEG polymers, wherein the conotoxin peptide analog is the conotoxin peptide analog is of Formula (Ib) (SEQ ID NO:104):
- R 2 is OH or NH 2 .
- a method of making a PEGylated conotoxin peptide analog or a pharmaceutically acceptable salt thereof comprising contacting under reaction conditions a conotoxin peptide analog or a salt thereof, with one or more reactive polyethylene glycol (PEG) polymers to form a PEGylated conotoxin peptide analog, wherein the reactive PEG polymers each comprise a reactive group covalently linked, optionally via a linking group, to a PEG polymer, and wherein each reactive group reacts under the reaction conditions to form a covalent bond with the conotoxin peptide analog whereby the conotoxin peptide analog is covalently attached directly or via a linking group to the one or more PEG polymers, wherein the amino acid sequence of the conotoxin peptide analog is Gly-Cys-X 3
- AA is selected from the group consisting of (S)-propargyl glycine, (S)-azidoalanine, (S)- homopropargyl glycine, (S)-azidohomoalanine, (S)-azidonorvaline and (S)-bishomopropargyl glycine;
- AA Citrulline
- AA is selected from the group consisting of (S)-azidohomoalanine, (S)-homopropargyl glycine, (S)-azidonorvaline, and (S)-bishomopropargyl glycine; wherein when X 3
- AA is selected from the group consisting of (S)-propargyl glycine, (S)- homopropargyl glycine, and (S)-bishomopropargyl glycine, X 12
- a A is (S)-azidohomoalanine or (S)-azidonorvaline; when X 3
- a A is selected from the group consisting of (S)-azidoalanine, (S)- azidohomoalanine, and (S)-azidonorvaline, X 12
- AA is (S)-homopropargyl glycine or (S)- bishomopropargyl glycine;
- a A is Tyr, Phe, Trp, or a D-isomer of Tyr, Phe, or Trp, and X 2
- AA is N-Me-Gly, D-Tyr, or N-Me-Tyr
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group.
- a method of making a PEGylated conotoxin peptide analog or a pharmaceutically acceptable salt thereof comprising contacting under reaction conditions a conotoxin peptide analog or a salt thereof, with one or more reactive polyethylene glycol (PEG) polymers to form a PEGylated conotoxin peptide analog, wherein the reactive PEG polymers each comprise a reactive group covalently linked, optionally via a linking group, to a PEG polymer, and wherein each reactive group reacts under the reaction conditions to form a covalent bond with the conotoxin peptide analog whereby the conotoxin peptide analog is covalently attached directly or via a linking group to the one or more PEG polymers, wherein the amino acid sequence of the conotoxin peptide analog is Gly-Cys-X 3
- AA is (S)-propargyl glycine
- AA Citrulline
- a A is 3-iodo-Tyr
- a A is (S)-azidonorvaline
- C-terminus of the conotoxin peptide analog is a carboxylic acid or an amide group.
- the reaction conditions are standard PEGylation conditions.
- the reaction conditions are conditions are standard amide formation conditions.
- Certain standard amide formation conditions are described in Valeur and Bradley, Chemical Society Reviews, 2009, 38:606-631.
- the amide formation conditions include presence of a coupling reagent such as dicyclohexylcarbodiimide (DCC), 1- hydroxy-1H-benzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), or 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
- DCC dicyclohexylcarbodiimide
- HOBt 1- hydroxy-1H-benzotriazole
- EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
- reaction conditions are conditions are standard amine formation conditions. In one embodiment, the amine formation conditions are reductive amination conditions. 6.
- RgIA conotoxin peptide analogs CSP-4-OH and CSP-4-NH2 have an amino acid sequence of Gly-Cys-Cys-Thr-Asp-Pro-Arg-Cys-(Cit)-(3-iodo-Tyr)-Gln-Cys-Tyr; where CSP-4- OH (SEQ ID NO:4) has a carboxylic acid group at the C-terminus and CSP-4-NH2 has an amide group at the C-terminus.
- CSP-4-desTyr-OH has an amino acid sequence of Gly-Cys- Cys-Thr-Asp-Pro-Arg-Cys-(Cit)-(3-iodo-Tyr)-Gln-Cys (SEQ ID NO:5), with a carboxylic acid at the C-terminus.
- CSP-4-NH2 The active conformation of CSP-4-NH2 consist of two disulfide bonds, one between Cys2 and Cys8, and a second between Cys3 and Cys12.
- the Cys2-8, Cys3-12“native” form of CSP-4-NH2 is active on both the human and rat a9a10 nAChR.
- a significant portion of the native form of CSP-4-NH2 underwent isomerization into a“ribbon” form, containing alternative disulfide bonds Cys2-Cys12 and Cys3- Cys8 and a“bead” form containing alternative Cys2-Cys3 and Cys8-Cys12 disulfide bonds.
- CSP-4-NH2 principally isomerized between the native and ribbon forms, with very little bead formation (Fig 1A, B). Neither the ribbon nor bead form were active on the human or rat a9a10 nAChR, suggesting that disulfide shuffling contributes to a reduction in potency of the molecule. Furthermore, the presence of a C-terminal amide in
- CSP-4-NH2 did not reduce isomerization relative to a C-terminal carboxylic acid in CSP-4–OH.
- disulfide isomerization also occurred in vivo following intravenous and subcutaneous injection of a 1 mg/kg dose of compound 6 to Sprague Dawley rats.
- At 1 h following injection only 40– 50 % of the recovered peptide from blood remained in the native form by HPLC- MS/MS analysis, indicating that disulfide isomerization occurs in vivo similar to observations in vitro.
- Disulfide shuffling of conotoxin peptide analogs CSP-4–OH and CSP-4-NH2 was demonstrated by incubating the peptides at a final concentration of 0.1– 0.5 mg/mL in serum or plasma from Sprague Dawley rat and human in vitro at 37 °C up to 24 h. Plasma samples were treated with anticoagulants including citrate, K2EDTA and heparin. Samples of the incubations were removed at several timepoints and for each timepoint, the resulting peptide isomers were extracted from the matrix by protein precipitation (3 volumes of methanol) followed by centrifugation of the precipitated sample at 10,000 x g through a Millipore Ultrafree-MC GV centrifugal filter.
- each CSP-4–OH and CSP-4-NH2 isomer was determined using LC-MS analysis on an Orbitrap Elite (FIG.1C). Aliquots of non-reduced sample were diluted 1:100 in water:acetonitrile:formic acid (98:2:0.1%) to an estimated concentration of 1.2-1.5 pmol/ ⁇ L. A 10 ⁇ L injection was made by an Easy-nLC II HPLC system (Thermo Scientific) onto a 75 mm i.d. PicoTipTM 25 cm long fused silica nano-column (New Objective) coupled to a 2 cm long, 100 mm i.d.
- IntegraFritTMtrap (New Objective).
- the column and the trap were configured in a vented configuration (Licklider, et al., Analytical Chemistry, 2002, 74, 3076-3082), with the column packed with 5mm size Magic C18 AQ reverse-phased media (100 ⁇ pore size, Michrom Bioresources, Auburn, CA) and the trap packed with the same material (200 ⁇ pore size, Michrom).
- the mass spectrometer was operated in the data dependent mode over the range of 400-1800 m/z. For each cycle of the instrument, the top 3 most abundant ions were selected from a precursor scan (with the orbitrap resolution set at 120k in the profile mode). MS/MS data were collected in the centroid mode using the same settings as listed above, with the exception that the isolation width was set to 2.0 m/z.
- the dynamic exclusion settings used were as follows: repeat count of 1, a 15 second count duration, an exclusion list size of 500 and an exclusion duration of 30 seconds.
- the native and ribbon isomers had the same mass-to-charge ratio as determined using mass spectrometry, indicating that the two HPLC peaks have the same identity (FIG.1C).
- Isolated ribbon isomer of CSP-4-NH2 was found to have no blocking activity on the human a9a10 nAChR.
- CSP-4-NH2 was incubated in human serum for one hour as described above, followed by preparative HPLC and collection of the peak corresponding to the ribbon isomer.
- the ribbon isomer was also chemically synthesized with the Cys2-Cys12 and Cys3- Cys8 disulfide connectivity. Chemically synthesized ribbon isomer and isomer isolated following incubation in human serum were tested for activity on the human a9a10 nAChR using two electrode voltage clamp electrophysiology.
- Example 1.1 Conotoxin Peptide Analog Ia (L-tyrosine, glycyl-L-cysteinyl-L- alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)-L-ornithyl- L-tryptophyl-L-glutaminyl-L-norvalyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 -(1H-1,2,3-triazole- 4,1-diyl)) (SEQ ID NO:6):
- 2-Chlorotrityl resin loaded with FMOC-Tyr(OtBu)-OH (1): 2-Chlorotrityl chloride resin (MFCD00040399, 15.0 g, 18 mmol) was added to a reaction vessel and was washed with CH 2 Cl 2 (100 mL) and then swelled in CH 2 Cl 2 (100 mL) for 10 min. After draining the reaction vessel, a solution of FMOC-Tyr(OtBu)-OH (2.5 g, 5.4 mmol) in CH2Cl2 (150 mL) was added, followed by dropwise addition of DIPEA (1.8 mL, 10.8 mmol). The reaction vessel was then shaken at room temperature for 1.5 h.
- the FMOC group was removed from the tethered Tyr group by treatment with 1:4 piperidine/DMF (2x100 mL, 15 min each), and then the resin was washed with DMF (6x100 mL). Then, HATU (3.80 g, 10 mmol), HOAt (1.35 g, 10 mmol), and DIPEA (2.5 mL, 15 mmol) were added with FMOC-5-azido-Nva-OH (CAS# 1097192-04-5, 3.80 g, 10 mmol) in DMF (100 mL). The reaction vessel was shaken for a minimum of 2.5 h, followed by washing with DMF (6x100 mL). Reaction completeness was determined by the Ninhydrin test. If negative
- FMOC-Gln(Trt)-OH (CAS#132327-80-1, 6.1 g, 10 mmol), FMOC-Trp(Boc)-OH (CAS#143824-78-6, 5.2 g, 10 mmol), FMOC-Cit-OH (CAS# 133174-15-9, 3.9 g, 10 mmol), FMOC-Cys(Trt)-OH (CAS# 103213-32-7, 5.8 g, 10 mmol), FMOC-Arg(Pbf)-OH (CAS# 154445-77-9, 6.4 g, 10 mmol), FMOC-Pro-OH (CAS# 71989-31-6, 3.3 g, 10 mmol), FMOC- Asp(OtBu)-OH (CAS# 71989-14-5, 4.1 g, 10 mmol), FMOC-Thr(tBu)-OH (CAS# 71989-35-0, 3.9 g, 10 mmol), FMOC-Pra
- Example 1.2 Conotoxin Peptide Analog Ia’ (L-tyrosinamide, glycyl-L- cysteinyl-L-alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)- L-ornithyl-L-tryptophyl-L-glutaminyl-L-norvalyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 -(1H- 1,2,3-triazole-4,1-diyl)) (SEQ ID NO:9):
- Conotoxin peptide analog Ia’ was synthesized by employing the same procedure described for Conotoxin peptide analog Ia’ using intermediate conotoxin peptide analog Za’ in lieu of compound 4.
- LC-MS single quad ESI
- m/z 1617.5 (M+1H)/ + (calculated MW: 1616.5); HPLC method E; retention time: 14.0 min; purity 96.9%.
- Example 1.3 Conotoxin Peptide Analog Ib (L-tyrosine, glycyl-L-cysteinyl-L- alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)-L-ornithyl- L-3-iodotyrosyl-L-glutaminyl-L-norvalyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 -(1H-1,2,3- triazole-4,1-diyl)) (SEQ ID NO:12):
- Conotoxin peptide analog Ib was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zb in lieu of compound 4.
- Example 1.4 Conotoxin Peptide Analog Ib’ (L-tyrosinamide, glycyl-L- cysteinyl-L-alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)- L-ornithyl-L-3-iodotyrosyl-L-glutaminyl-L-norvalyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 -(1H- 1,2,3-triazole-4,1-diyl)) (SEQ ID NO:15):
- Intermediate conotoxin peptide analog Yb’ H-Gly-Cys-Pra-Thr-Asp-Pro-Arg- Cys-Cit-3-I-Tyr-Gln-5-azidoNVa-Tyr-NH2 (SEQ ID NO:16): Intermediate conotoxin peptide analog Yb’ was synthesized by employing the same procedure described for intermediate conotoxin peptide analog Yb using a Rink Amide resin MFCD00677976 in lieu of 2-Chlorotrityl chloride resin MFCD00040399 in the solid phase peptide sythesis.
- Conotoxin peptide analog Ib’ was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zb’ in lieu of compound 4.
- Example 1.4 Conotoxin Peptide Analog Ic (L-tyrosinamide, glycyl-L-alanyl- L-cysteinyl-L-threonyl-L- a -aspartyl-L-prolyl-L-arginyl-L-norvalyl-N5-(aminocarbonyl)-L- ornithyl-L-3-iodotyrosyl-L-glutaminyl-L-cysteinyl-cyclic 2 3 ,8 5 -(1H-1,2,3-triazole-4,1-diyl)- cyclic -(3®12)-disulfide) (SEQ ID NO:18):
- Intermediate conotoxin peptide analog Yc (H-Gly-Pra-Cys-Thr-Asp-Pro-Arg-5- azidoNVa-Cit-3-I-Tyr-Gln-Cys-Tyr-NH2) (SEQ ID NO:19): Intermediate conotoxin peptide analog Yc was synthesized by employing the same procedure described for intermediate conotoxin peptide analog Yb’ using FMOC-Cys(Trt)-OH in lieu of FMOC-5-azido-Nva-OH (the 12-position residue), FMOC-5-azido-Nva-OH in lieu of FMOC-Cys(Trt)-OH (the 8-position residue), FMOC-Cys(Trt)-OH in lieu of FMOC-Pra-OH (the 3-position residue), and FMOC- Pra-OH in lieu of FMOC-Cys(Trt)-OH (the 2-position residue) in the solid phase peptid
- Conotoxin peptide analog Ic was synthesized by employing the same procedure described for conotoxin peptide analog Ib’ using intermediate conotoxin peptide analog Zc in lieu of Intermediate conotoxin peptide analog Zb’.
- LC-MS (ESI-TOF) m/z: 574.2 [M+3H]/3 + , 860.7 [M+2H]/2 + (calculated MW: 1719.55); HPLC method B; retention time: 10.2 min; Purity 98.3%.
- Example 1.5 Conotoxin Peptide Analog Id (L-tyrosinamide, glycyl-L- norvalyl-L-cysteinyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-alanyl-N5-(aminocarbonyl)- L-ornithyl-L-3-iodotyrosyl-L-glutaminyl-L-cysteinyl-cyclic 2 5 ,8 3 -(1H-1,2,3-triazole-1,4-diyl)- cyclic -(3®12)-disulfide) (SEQ ID NO:21):
- Intermediate conotoxin peptide analog Yd H-Gly-5-azidoNVa-Cys-Thr-Asp-Pro- Arg-Pra-Cit-3-I-Tyr-Gln-Cys-Tyr-NH2) (SEQ ID NO:22): Intermediate conotoxin peptide analog Yd was synthesized by employing the same procedure described for intermediate conotoxin peptide analog Yb’ using FMOC-Cys(Trt)-OH in lieu of FMOC-5-azido-Nva-OH (the 12-position residue), FMOC-Pra-OH in lieu of FMOC-Cys(Trt)-OH (the 8-position residue), FMOC-Cys(Trt)-OH in lieu of FMOC-Pra-OH (the 3-position residue), and FMOC-5-azido- Nva-OH in lieu of FMOC-Cys(Trt)-OH (the 2-position residue) in the
- Intermediate conotoxin peptide analog Zd H-Gly-5-azidoNVa-Cys-Thr-Asp-Pro- Arg-Pra-Cit-3-I-Tyr-Gln-Cys-Tyr-NH2, (Cys3®Cys12) disulfide bridge) (SEQ ID NO:23): Intermediate conotoxin peptide analog Zd was synthesized by employing the same procedure described for intermediate conotoxin peptide analog Zb’ using intermediate conotoxin peptide analog Yd in lieu of intermediate conotoxin peptide analog Yb’.
- Conotoxin peptide analog Id was synthesized by employing the same procedure described for conotoxin peptide analog Ib’ using intermediate conotoxin peptide analog Zd in lieu of intermediate conotoxin peptide analog Zb’.
- Example 1.6 Conotoxin Peptide Analog Ie (L-tyrosinamide, glycyl-L- cysteinyl-L-norvalyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5- (aminocarbonyl)-L-ornithyl-L-3-iodotyrosyl-L-glutaminyl-L-alanyl-cyclic (2®8)-disulfide- cyclic 3 5 ,12 3 -(1H-1,2,3-triazole-1,4-diyl)) (SEQ ID NO:24):
- Intermediate conotoxin peptide analog Ye (H-Gly-Cys-5-azidoNVa-Thr-Asp-Pro- Arg-Cys-Cit-3-I-Tyr-Gln-Pra-Tyr-NH2) (SEQ ID NO:25): Intermediate conotoxin peptide analog Ye was synthesized by employing the same procedure described for intermediate conotoxin peptide analog Yb’ using FMOC-Pra-OH in lieu of FMOC-5-azido-Nva-OH (the 12- position residue) and FMOC-5-azido-Nva-OH in lieu of FMOC-Pra-OH (the 3-position residue) in the solid phase peptide synthesis.
- Conotoxin peptide analog Ie was synthesized by employing the same procedure described for conotoxin peptide analog Ib’ using intermediate conotoxin peptide analog Ze in lieu of intermediate conotoxin peptide analog Zb’.
- Intermediate conotoxin peptide analog Yf H-Gly-Cys-Pra-Thr-Asp-Pro-Arg-Cys- Cit-3-I-Tyr-Gln-3-azidoAla-Tyr-NH2) (SEQ ID NO:28): Intermediate conotoxin peptide analog Yf was synthesized by employing the same procedure described for intermediate conotoxin peptide analog Yb’ using FMOC-3-azido-Ala-OH in lieu of FMOC-Pra-OH (the 12- position residue) and FMOC-Pra-OH in lieu of FMOC-5-azido-Nva-OH (the 3-position residue) in the solid phase peptide synthesis.
- Intermediate conotoxin peptide analog Zf H-Gly-Cys-Pra-Thr-Asp-Pro-Arg-Cys- Cit-3-I-Tyr-Gln-3-azidoAla-Tyr-NH2, (Cys2®Cys8) disulfide bridge) (SEQ ID NO:29): Intermediate conotoxin peptide analog Zf was synthesized by employing the same procedure described for intermediate conotoxin peptide analog Zb’ using intermediate conotoxin peptide analog Yf in lieu of intermediate conotoxin peptide analog Yb’.
- Conotoxin peptide analog If was synthesized by employing the same procedure described for conotoxin peptide analog Ib’ using intermediate conotoxin peptide analog Zf in lieu of intermediate conotoxin peptide analog Zb’.
- Example 1.8 Conotoxin Peptide Analog Ig (L-tyrosine, glycyl-L-cysteinyl- (2S)-2-aminobutanoyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5- (aminocarbonyl)-L-ornithyl-L-tryptophyl-L-glutaminyl-L-norvalyl-cyclic (2®8)-disulfide-cyclic 3 4 ,12 5 -(1H-1,2,3-triazole-4,1-diyl)) (SEQ ID NO:30):
- Intermediate conotoxin peptide analog Yg H-Gly-Cys-homoPra-Thr-Asp-Pro- Arg-Cys-Cit-Trp-Gln-5-azidoNva-Tyr-OH
- SEQ ID NO:31 Intermediate conotoxin peptide analog Yg was synthesized by employing the same procedure described for compound 3 using FMOC-homopropargyl glycine in lieu of FMOC-Pra-OH (the 3-position residue) in the solid phase peptide synthesis.
- Conotoxin peptide analog Ig was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zg in lieu of compound 4.
- LC-MS single quad ESI
- m/z 545.0 [M+3H]/3 + , 817.3 [M+2H]/2 + (calculated MW: 1631.67); HPLC method A; retention time: 12.5 min; purity 98.2%.
- Example 1.9 Conotoxin Peptide Analog Ih (L-tyrosine, glycyl-L-cysteinyl- (2S)-2-aminobutanoyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5- (aminocarbonyl)-L-ornithyl-L-tryptophyl-L-glutaminyl-L-(2S)-2-aminobutanoyl-cyclic (2®8)- disulfide-cyclic 3 4 ,12 4 -(1H-1,2,3-triazole-4,1-diyl)) (SEQ ID NO:33):
- Intermediate conotoxin peptide analog Yh H-Gly-Cys-homoPra-Thr-Asp-Pro- Arg-Cys-Cit-Trp-Gln-azidohomoAla-Tyr-OH
- SEQ ID NO:34 Intermediate conotoxin peptide analog Yh was synthesized by employing the same procedure described for compound 3 using FMOC-homopropargyl glycine in lieu of FMOC-Pra-OH (the 3-position residue) and FMOC-g-azido-homoalanine in lieu of FMOC-5-azido-Nva-OH (the 12-position residue) in the solid phase peptide synthesis.
- Conotoxin peptide analog Ih was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zh in lieu of compound 4.
- LC-MS single quad ESI
- m/z 540.6 [M+3H]/3 + , 809.9 [M+2H]/2 + (calculated MW: 1617.66); HPLC method A; retention time: 12.4 min; purity 83.9%.
- Example 1.10 Conotoxin Peptide Analog Ii (L-tyrosine, glycyl-L-cysteinyl- (2S)-2-aminobutanoyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5- (aminocarbonyl)-L-ornithyl-L-tryptophyl-L-glutaminyl-L-(2S)-2-aminobutanoyl-cyclic (2®8)- disulfide-cyclic 3 4 ,12 4 -(1H-1,2,3-triazole-1,4-diyl)) (SEQ ID NO:36):
- Conotoxin peptide analog Ii was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zi in lieu of compound 4.
- LC-MS single quad ESI
- m/z 540.7 [M+3H]/3 + , 810.5 [M+2H]/2 + (calculated MW: 1617.66); HPLC method A; retention time: 12.3 min; purity 85.8%.
- Example 1.11 Conotoxin Peptide Analog Ij (L-tyrosine, glycyl-L-cysteinyl- (2S)-2-aminopentanoyl-L-alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5- (aminocarbonyl)-L-ornithyl-L-3-iodotyrosyl-L-glutaminyl-L-alanyl-cyclic (2®8)-disulfide- cyclic 3 5 ,12 3 -(1H-1,2,3-triazole-4,1-diyl)) (SEQ ID NO:39):
- Intermediate conotoxin peptide analog Yj H-Gly-Cys-bishomoPra-Thr-Asp-Pro- Arg-Cys-Cit-Trp-Gln-3-azidoAla-Tyr-OH
- SEQ ID NO:40 Intermediate conotoxin peptide analog Yj was synthesized by employing the same procedure described for compound 3 using FMOC-bis-homopropargyl glycine in lieu of FMOC-Pra-OH (the 3-position residue) and FMOC-3-azido-Ala-OH in lieu of FMOC-5-azido-Nva-OH (the 12-position residue) in the solid phase peptide synthesis.
- Conotoxin peptide analog Ij was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zj in lieu of compound 4.
- LC-MS single quad ESI
- m/z 540.5 [M+3H]/3 + , 810.1 [M+2H]/2 + (calculated MW: 1617.66); HPLC method A; retention time: 12.04 min; purity 97.6%.
- Example 1.12 Conotoxin Peptide Analog Ik (L-tyrosine, glycyl-L-cysteinyl-L- alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)-L-ornithyl- L-tryptophyl-L-glutaminyl-L-(2S)-2-aminopentanoyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 -(1H- 1,2,3-triazole-1,4-diyl)) (SEQ ID NO:42):
- Intermediate conotoxin peptide analog Yk (H-Gly-Cys-3-azidoAla-Thr-Asp-Pro- Arg-Cys-Cit-Trp-Gln-bishomoPra-Tyr-OH) (SEQ ID NO:43): Intermediate conotoxin peptide analog Yk was synthesized by employing the same procedure described for compound 3 using FMOC-3-azido-Ala-OH in lieu of FMOC-Pra-OH (the 3-position residue) and FMOC-bis- homopropargyl glycine in lieu of FMOC-5-azido-Nva-OH (the 12-position residue) in the solid phase peptide synthesis.
- Conotoxin peptide analog Ik was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zk in lieu of compound 4.
- LC-MS single quad ESI
- m/z 540.6 [M+3H]/3 + , 810.0 [M+2H]/2 + (calculated MW: 1617.66); HPLC method A; retention time: 12.24 min; purity 97.6%.
- Example 1.13 Conotoxin Peptide Analog Il (L-phenylalanine, glycyl-L- cysteinyl-L-alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)- L-ornithyl-L-tryptophyl-L-glutaminyl-L-norvalyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 -(1H- 1,2,3-triazole-4,1-diyl)) (SEQ ID NO:45):
- Intermediate conotoxin peptide analog Yl (H-Gly-Cys-Pra-Thr-Asp-Pro-Arg-Cys- Cit-Trp-Gln-5-azidoNVa-Phe-OH) (SEQ ID NO:46): Intermediate conotoxin peptide analog Yl was synthesized by employing the same procedure described for compound 3 using FMOC- Phe(OtBu)-OH-loaded 2-chlorotrityl resin loaded FMOC-Phe(OtBu)-OH (5) in lieu of the FMOC-Tyr(OtBu)-loaded 2-chlorotrityl resin (1) as the C-terminus start in the solid phase peptide synthesis.
- Conotoxin peptide analog Il was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zl in lieu of compound 4.
- LC-MS single quad ESI
- m/z 535.2 [M+3H]/3 + , 802.2 [M+2H]/2 + (calculated MW: 1601.66); HPLC method A; retention time: 13.47 min; purity 95.6%.
- Example 1.14 Conotoxin Peptide Analog Im (D-tyrosine, glycyl-L-cysteinyl-L- alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)-L-ornithyl- L-tryptophyl-L-glutaminyl-L-norvalyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 -(1H-1,2,3-triazole- 4,1-diyl)) (SEQ ID NO:48):
- 2-Chlorotrityl resin loaded FMOC-D-Tyr(OtBu)-OH was synthesized by employing the same procedure described for 2- Chlorotrityl resin 1 using FMOC-D-Tyr(OtBu)-OH in lieu of FMOC-Tyr(OtBu)-OH.
- Intermediate conotoxin peptide analog Ym H-Gly-Cys-Pra-Thr-Asp-Pro-Arg-Cys- Cit-Trp-Gln-5-azidoNVa-D-Tyr-OH
- SEQ ID NO:49 Intermediate conotoxin peptide analog Ym was synthesized by employing the same procedure described for compound 3 using FMOC- D-Tyr(OtBu)-OH-loaded 2-chlorotrityl resin (6) in lieu of the FMOC-Tyr(OtBu)-loaded 2- chlorotrityl resin (1) as the C-terminus start in the solid phase peptide synthesis.
- Conotoxin peptide analog Im was synthesized by employing the same procedure described for conotoxin peptide analog Ia using intermediate conotoxin peptide analog Zm in lieu of compound 4.
- LC-MS single quad ESI
- m/z 540.6 [M+3H]/3 + , 810.0 [M+2H]/2 + (calculated MW: 1617.66); HPLC method A; retention time: 12.07 min; purity 86.6%.
- Example 1.15 Conotoxin Peptide Analog In (glycine, glycyl-L-cysteinyl-L- alanyl-L-threonyl-L-a-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-N5-(aminocarbonyl)-L-ornithyl- L-tryptophyl-L-glutaminyl-L-norvalyl-L-tyrosyl-N-methyl-cyclic (2®8)-disulfide-cyclic 3 3 ,12 5 - (1H-1,2,3-triazole-4,1-diyl)) (SEQ ID NO:51):
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/012307 WO2020142102A1 (en) | 2019-01-04 | 2019-01-04 | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3906253A1 true EP3906253A1 (en) | 2021-11-10 |
Family
ID=65244618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19702500.0A Withdrawn EP3906253A1 (en) | 2019-01-04 | 2019-01-04 | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP3906253A1 (en) |
JP (1) | JP2022522935A (en) |
KR (1) | KR20210116505A (en) |
CN (1) | CN113966339A (en) |
AU (1) | AU2019418319A1 (en) |
BR (1) | BR112021013302A2 (en) |
CA (1) | CA3125383A1 (en) |
CL (1) | CL2021001775A1 (en) |
CO (1) | CO2021008845A2 (en) |
CR (1) | CR20210363A (en) |
IL (1) | IL284574A (en) |
MX (1) | MX2021008070A (en) |
PE (1) | PE20211734A1 (en) |
SG (1) | SG11202106847SA (en) |
WO (1) | WO2020142102A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230033485A (en) | 2021-09-01 | 2023-03-08 | 삼성전자주식회사 | Storage device and operating method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9284358B2 (en) * | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
EP2051726B1 (en) * | 2006-07-18 | 2018-04-18 | University of Utah Research Foundation | Methods for treating pain and screening analgesic compounds |
EP2310407A4 (en) * | 2008-04-08 | 2011-09-14 | Aileron Therapeutics Inc | Biologically active peptidomimetic macrocycles |
CN102875654B (en) * | 2012-09-25 | 2014-07-09 | 中国人民解放军军事医学科学院生物工程研究所 | Method for preparing conotoxin polypeptide Eb1.6 |
WO2014144842A2 (en) * | 2013-03-15 | 2014-09-18 | Rhythm Metabolic, Inc. | Pharmaceutical compositions |
US11014970B2 (en) * | 2014-11-07 | 2021-05-25 | Kineta Chronic Pain, Llc | Modifications and uses of conotoxin peptides |
-
2019
- 2019-01-04 AU AU2019418319A patent/AU2019418319A1/en active Pending
- 2019-01-04 MX MX2021008070A patent/MX2021008070A/en unknown
- 2019-01-04 EP EP19702500.0A patent/EP3906253A1/en not_active Withdrawn
- 2019-01-04 CR CR20210363A patent/CR20210363A/en unknown
- 2019-01-04 PE PE2021001115A patent/PE20211734A1/en unknown
- 2019-01-04 JP JP2021538994A patent/JP2022522935A/en active Pending
- 2019-01-04 SG SG11202106847SA patent/SG11202106847SA/en unknown
- 2019-01-04 WO PCT/US2019/012307 patent/WO2020142102A1/en unknown
- 2019-01-04 CN CN201980093540.XA patent/CN113966339A/en active Pending
- 2019-01-04 BR BR112021013302-0A patent/BR112021013302A2/en unknown
- 2019-01-04 CA CA3125383A patent/CA3125383A1/en active Pending
- 2019-01-04 KR KR1020217024613A patent/KR20210116505A/en not_active Application Discontinuation
-
2021
- 2021-07-02 CL CL2021001775A patent/CL2021001775A1/en unknown
- 2021-07-02 IL IL284574A patent/IL284574A/en unknown
- 2021-07-02 CO CONC2021/0008845A patent/CO2021008845A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020142102A9 (en) | 2020-11-19 |
SG11202106847SA (en) | 2021-07-29 |
JP2022522935A (en) | 2022-04-21 |
CA3125383A1 (en) | 2020-07-09 |
CO2021008845A2 (en) | 2021-10-29 |
CL2021001775A1 (en) | 2022-05-27 |
MX2021008070A (en) | 2021-10-13 |
AU2019418319A1 (en) | 2021-07-22 |
CR20210363A (en) | 2021-12-10 |
KR20210116505A (en) | 2021-09-27 |
CN113966339A (en) | 2022-01-21 |
BR112021013302A2 (en) | 2021-09-14 |
IL284574A (en) | 2021-08-31 |
PE20211734A1 (en) | 2021-09-06 |
WO2020142102A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2862038C (en) | Peptidomimetic macrocycles | |
EP3062823B1 (en) | Novel polypeptides | |
CN110229216B (en) | Compstatin peptides with improved pharmacokinetic properties | |
AU2012326026B2 (en) | Peptidomimetic macrocyles | |
KR100905380B1 (en) | Peptides with neuropeptide-2 receptory2r agonist activity | |
KR100558131B1 (en) | A pharmaceutical composition comprising melanocortin receptor ligands and a manufacture of a medicament comprising melanocornin receptor ligands | |
AU2018201599A1 (en) | Novel a4B7 peptide dimer antagonists | |
WO2015200916A2 (en) | Hepcidin and mini-hepcidin analogues and uses therof | |
KR20060014444A (en) | Melanocortin receptor 4 (mc4) agonists and their uses | |
WO2016054445A1 (en) | Novel cyclic monomer and dimer peptides having integrin antagonist activity | |
WO2017023933A2 (en) | Peptidomimetic macrocycles | |
JP2012510798A (en) | Peptide therapeutic agent conjugates and uses thereof | |
US20240293511A1 (en) | Hepcidin mimetics for treatment of hereditary hemochromatosis | |
JP2023540679A (en) | Conjugated hepcidin mimetics | |
WO2018128828A1 (en) | Novel hepcidin mimetics and uses thereof | |
WO2012055770A1 (en) | Glucose-dependent insulinotropic peptide analogs | |
US5204328A (en) | Peptides having atrial natriuretic factor activity | |
KR20220066287A (en) | Compstatin analogs and medicinal uses thereof | |
US8709998B2 (en) | Peptide vectors | |
WO2001098324A1 (en) | Peptide conjugates modified n- and/or c-terminally by short charged peptide chains | |
AU2015323769A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
US11612661B2 (en) | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions | |
AU2009246894A1 (en) | Pharmaceutical compositions of somatostatin-dopamine conjugates | |
US11975040B2 (en) | Plexin binding regulator | |
KR20230039718A (en) | Inhibitors of complement factor C3 and their medical uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210701 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40063646 Country of ref document: HK |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240115 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20240701 |